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Motivation:  Bone mineral density (BMD), the principal determinant of bone strength and a risk 
factor for osteoporosis, is the net result of two processes:  (i) the acquisition of peak BMD during 
young adulthood, and (ii) the subsequent rate of bone loss with age.  While the genetics of peak 
BMD has been extensively studied, the specific genetic polymorphisms influencing peak BMD 
and the genetic contribution to bone loss are largely unknown.  We investigated the extent to 
which genes influence 5-year change in BMD and searched for specific chromosomal regions 
influencing peak BMD and change in BMD in 1047 Mexican Americans from 34 large, 
multigenerational families.     
 
Methods:  BMD measurements of the hip, spine, and forearm were collected at baseline and 
follow-up (3-8 years later, mean = 5.6 years) by dual-energy x-ray absoptiometry, from which 
annual BMD change was calculated.  Pedigree-based maximum likelihood methods modeling the 
variance decomposition of longitudinal and cross-sectional measurements of BMD were used to 
estimate heritability (h2) and perform genome-wide linkage analysis (using a 7.6 cM genetic 
map) for BMD change and peak BMD.  The effects of several environmental covariates, notably 
sex, age, weight, change in weight, and menopause, were simultaneously modeled. 
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Results:  We determined that change in BMD varied over time and could be categorized into 
two heritable (h2 = 31% to 44%) phases: early adult bone loss in participants <45 years of age 
and later bone loss in participants >45 years of age.  A quantitative trait locus (QTL) influencing 
early bone loss was observed on chromosome 1q (LOD = 3.6) in the cohort <45 years; no 
specific chromosomal regions influencing change in BMD were observed in the cohort >45 
years.  By comparing cross-sectional genetic analyses at baseline and follow-up, we identified 
QTLs on chromosomes 6q and 13q with consistent effects on peak BMD of the hip and showed 
that QTLs influencing peak BMD did not overlap with QTLs influencing bone loss. 
 
Public health significance:  This work demonstrated the importance of genes in the etiology of 
osteoporosis, a growing public health problem.  Understanding the genetic determinants of bone 
strength could lead to new biological targets for the treatment of osteoporosis, and/or the 
identification of persons at risk who would benefit from preventative interventions. 
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1.0  INTRODUCTION 
1.1 PUBLIC HEALTH SIGNIFICANCE OF OSTEOPOROSIS 
Osteoporosis is a skeletal condition of major public health significance, contributing toward risk 
of fragility fracture in women and men of all populations.  The degenerative disorder and 
associated fragility fractures have devastating effects on health, resulting in substantial morbidity 
for all osteoporotic fractures, and increased mortality for hip and vertebral fractures (1).   
Characterized by low bone mass and deterioration of bone micro-architecture, osteoporosis 
affects 30% of postmenopausal women (2) and increases in prevalence to 70% for those women 
80 years and older (3).  The incidence of this condition and the corresponding financial burden of 
treatment are projected to increase as the American population ages; indeed, heath care 
expenditures for treatment of osteoporotic fractures were $14 billion in 1995 (4), and the 
estimated annual cost for treating hip fractures alone may exceed $250 billion in the next 40 
years (5).  Thus, osteoporosis and its related morbidities, mortality, and economic costs represent 
a serious public health problem.  
Advanced age is the most important risk factor for osteoporosis, and is associated with 
decline in both bone mass and bone quality.  However, many other risk factors for low bone 
mass have also been identified.  A number of lifestyle and healthcare-related factors (enumerated 
in Table 1.1) are known to affect bone mass (3,6), and because many of these are largely 
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modifiable, they provide means through which preventative lifestyle changes can help reduce 
risk.  On the other hand, many non-modifiable factors contributing to reduced bone mass also 
exist (3,6). Of these, family history and ancestry (which are partly indicative of underlying 
genetic risk factors) are of particular interest in this dissertation, which investigates the genetics 
of longitudinal bone loss and examines the changing role of genes on bone mass over the adult 
lifespan in Mexican Americans.   
 
Table 1.1.  Risk factors for low bone mass 
Modifiable  Non-modifiable 
smoking age 
alcohol consumption female sex 
low vitamin D family history of osteoporosis 
low calcium intake prior fragility fracture 
low physical activity  Caucasian or Asian ancestry 
low weight / weight loss low birth weigh 
stress / depression lactose intolerance 
surgical or drug induced hypogonadism early menopause 
glucocorticoid therapy  numerous co-morbidities / malignancies 
 
 
Substantial ethnic and geographic variation in bone mass (7-19), owing to differences in 
environmental and genetic risk factors, echoes the varying degree of burden of osteoporosis 
across populations.  In the United States, for example, Mexican Americans have greater bone 
mass, on average, than non-Hispanic whites, and lower bone mass than African Americans (18).  
Likewise, considerable variation in osteoporosis, fragility fractures, and bone mass among 
populations in Latin American (e.g. Argentina, Brazil, Chile, Columbia, Cuba, Mexico, Peru, 
Venezuela and others) has been reported (19).  The importance of environmental factors 
notwithstanding, the enormous variation in genetic ancestry among Latin American populations, 
resulting from varying degrees of admixture between European, Native American, African, and 
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Eastern Asian parental groups, is likely responsible for part of the variation in osteoporotic risk 
among populations from these countries.  Moreover, rapid population expansion and increased 
longevity in many developing nations has led to the growing societal impact of osteoporosis 
(20).  Despite differences in total burden among ethnically- and geographically-defined 
populations, osteoporosis embodies a growing concern, worldwide (19,20).  Understanding the 
environmental and genetic determinants of bone mass, including those in under-represented 
populations such as Mexican Americans, may lead to better prevention, risk assessment, and 
treatment of osteoporosis.   
1.2 COMPONENTS OF BONE STRENGTH:  BONE MASS AND BONE QUALITY 
Human bone is classified into two types distinguishable by porosity and microstructure:  (i) 
cortical bone, which is the dense outer shell and shaft of long bones, and (ii) trabecular bone, 
which is porous bone comprised of a network of rod- and plate-like supports called trabeculae.  
While different anatomical sites (e.g. ultradistal radius and midpoint radius) have different 
proportions of cortical and trabecular bone, both of these types of bone are important in the study 
of osteoporosis.   
The risk of bone fracture is related to two components of bone strength:  bone mass and 
bone quality.  The latter is a poorly defined and difficult-to-measure characteristic of bone, 
which encompasses microarchitecture and distribution of mineral within bone, as well as bone 
geometry and turnover.  Quality of bone microarchitecture refers to how the trabeculae are 3-
dimensionally interconnected in a structural lattice, specifically the abundance, thickness, and 
spacing of trabeculae, as well as cortical thickness and porosity.  Mineralization is also an 
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important characteristic for quality bone as newly laid bone requires time to fully mineralize; 
thus rapid remodeling can result in temporarily decreased bone quality.  Bone turnover, related to 
both microarchitecture and mineralization, refers to the dynamic processes of bone resorption 
and formation.  Tipping the balance of these two processes leads to resorption cavities within the 
bone, resulting in loss of bone quality.  In addition to the small-scale structural aspects of bone 
matrix, gross bone geometry is also a major component of bone quality.  The magnitude of bone 
dimensions, including external diameter and cortical thickness, partially determine the 
mechanical strength of bone, and may be responsible for much of the difference in bone strength 
between men and women (21).   
Interest in bone quality is increasing along with the development of imaging technology 
and capacity for computer modeling (21).  As the technology to practically assess certain 
components of bone quality become available, studies investigating these aspects of bone 
strength may provide new insights into the pathogenesis, diagnosis, and treatment of 
osteoporosis.  However, until recently, most epidemiological and genetic studies of osteoporosis 
have not specifically addressed measures of bone quality, due largely to the difficulty in 
assessing such characteristics.  Instead, much work has focused on phenotypes related to bone 
mass, which are easily measured, and account for 70% or more of the variation in bone strength 
(3).  
Bone mass is typically quantified in terms of bone mineral density (BMD), which is 
defined as mineral mass (g) distributed across a 2-dimensional projected area (cm2) or 3-
dimensional volume (cm3).  Measurable BMD (g/cm2 or g/cm3) is the net result of at least two 
processes:  (i) the acquisition of peak bone mass during young adulthood, and (ii) the subsequent 
loss of bone with age.  While BMD is a very accurate indicator of bone strength, there are some 
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limitations to using this measure.  For one, BMD is frequently calculated from a 2-dimensional 
projected area, which does not fully represent bone size.  Also, decline in BMD may be 
reflective of either loss of mineral mass or increase in bone area, which complicates 
interpretation of longitudinal changes in BMD.  BMD, and specifically the acquisition of peak 
bone mass and its apparent decline over the lifespan has been the subject of a number of 
epidemiological studies. 
1.3 GENETIC EPIDEMIOLOGY OF BONE MINERAL DENSITY 
Because of its public health implications, a large body of work has sought to identify 
environmental and genetic factors related to osteoporosis, and specifically BMD.  Numerous 
environmental risk factors for reduced BMD have been enumerated above.  The high heritability 
of BMD (30% to 80% depending on skeletal site and population) has long been known and 
demonstrated in many populations (17,22-32).  Mapping of specific quantitative trait loci (QTLs) 
implicated in BMD has been the goal of several studies.  Table 1.2 enumerates the findings from 
the many linkage analysis scans seeking to identify chromosomal regions that affect variation in 
BMD (33-57).  QTLs have been observed on nearly every chromosome, with some regions 
implicated in multiple studies, and others identified in a single study.  Inconsistency of linkage 
results among these studies may be reflective of the complexity of regulation of BMD, including:  
(i) genetic heterogeneity among populations, (ii) differences in environmental risk factors, 
demographics, and their interactions with genes, and (iii) differences in elements of study design, 
such as sample size, family size, phenotype assessment, inclusion criteria, statistical power, and 
types I and II error.   
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Table 1.2.  Chronological summary of previous linkage analyses for BMD (LOD > 2.0) 
 
Reference Population Sample Trait Region LOD 
Johnson et al.,  1997 Caucasian, US ped = 1, n = 22 spine 11q12 5.74 
Devoto et al.,  1998 Caucasian, Canada ped = 7, n = 149 femoral neck 1p36 2.29 
   spine 2p23 2.25 
   femoral neck 4qter 2.28 
Koller et al.,  1998 Mixed, US sibs = 374, n = 835 femoral neck 11q12 3.50 
   Ward's 11q12 2.84 
Niu et al.,  1999 Chinese, China ped = 96, n = 218 wrist 2 2.15 
Koller et al.,  2000 Mixed women, US ped = 286, n = 636 spine 1q21 3.11 
   femoral neck 5q33 2.03 
   femoral neck 6p11 2.13 
Devoto et al.,  2001 Caucasian, Canada ped = 42, n = 254 femoral neck 1p36 3.02 
Deng et al.,  2002 Caucasian, US ped = 53, n = 630 spine 4q13 3.08 
   spine 12q24 2.17 
   spine 13q33 2.43 
   wrist  4q32 2.26 
   femoral neck 10q26 2.29 
Karasik et al.,  2002 Caucasian, US ped = 330, n = 1557 Ward's 8q24 2.13 
   trochanter 21q22 2.39 
   spine 12q24 2.08 
   femoral neck 6p21 2.93 
   trochanter 21qter 3.14 
Styrkarsdottir et al.,  2003 Caucasian, Iceland ped = 207, n = 1323 hip + spine 6p 2.06 
   hip + spine 17p 2.02 
   spine 18p 2.12 
   hip + spine 20p12 5.10 
Wilson et al.,  2003 Caucasian, UK ped = 1094, n = 2188 whole body 1p36 2.38 
   spine 3p22 2.72 
   spine 16q12 2.11 
  ped =  254, n = 587 spine 3.p22 2.07 
Karasik et al.,  2003 Caucasian, US ped = 330, n = 1557 Ward's 8q24 2.13 
   trochanter 21qter 3.14 
  (men only) femoral neck 4q34 2.06 
  (women only) trochanter 12q23 3.00 
  (<60 years) femoral neck 9q22 2.71 
   spine 14q31 2.48 
  (>60 years) trochanter 17p13 2.03 
   Ward's 17p13 2.31 
Kammerer et al.,  2003 Mexican Am., US ped = 29, n = 664 wrist 4p 4.33 
   trochanter 6q27 2.27 
   femoral neck 2pter 3.98 
   femoral neck 8p21 2.15 
   trochanter 13q14 3.46 
      femoral neck 13q14 2.51 
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Table 1.2.  (continued)  
 
Reference Population Sample Trait Region LOD 
Karasik et al.,  2004 Caucasian, US ped = 323, n = 1203 P.C. 2 1p36 2.10 
   P.C. 1 1q21 2.10 
   P.C. 1 8q24 2.20 
   hip P.C. 16p13 2.00 
Huang et al.,  2004 Caucasian, US ped = 79, n = 1896 NA no LOD >2 
Shen et al.,  2004 Caucasian, US ped = 79, n = 1896 spine 7p14 2.64 
   spine 11q23 3.13 
   femoral neck Xp11 2.15 
   femoral neck Xq27 2.57 
   wrist Xq21 2.54 
   wrist Xq26 2.87 
   wrist Xq27 4.30 
  ped = 26, n = 1058 spine 20p12 2.33 
   femoral neck 4q35 2.14 
   femoral neck 11q12 2.04 
   femoral neck 15q23 2.00 
   femoral neck 20p12 2.33 
   femoral neck Xq26 2.23 
   wrist 20p13 2.55 
Econs et al.,  2004 Caucasian women, US ped = 134, n = 602 spine 1q21 4.30 
Peacock et al.,  2004 Caucasian women, US peds = 381, n = 842 trochanter 14q 3.05 
 African Am. women peds = 132, n = 293 Ward's 14q 2.58 
   princ. comp. 14q 2.60 
   femoral neck 15q 3.43 
   Ward's 15q 2.00 
   princ. comp. 15q 2.10 
Ralston et al.,  2005 Caucasian, UK ped = 715, n = 3691    
  (men only) spine 3q25 2.43 
   femoral neck 4q25 2.22 
   femoral neck 7p14 2.28 
   femoral neck 10q21 4.42 
   femoral neck 16p13 2.52 
  (women only) femoral neck 4q25 2.55 
   spine 18p11 2.83 
   spine 20q13 3.20 
   femoral neck 16q23 2.28 
Devoto et al.,  2005 Caucasian, Canada ped = 40, n < 254 femoral neck 1p36 2.87 
      spine 7p15 2.15 
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Table 1.2.  (continued)  
 
Reference Population Sample Trait Region LOD 
Peacock et al.,  2005 Mixed men, US ped = 225, n = 482 spine 1q 3.13 
   spine 2p 3.16 
   spine 14p 4.60 
   femoral neck 2q 2.99 
   femoral neck 18 2.37 
   Ward's 21 2.78 
Cheung et al., 2006 Chinese, China ped = 306, n = 1459 spine 1q 2.36 
Huang et al.,  2006 Chinese, China ped = 306, n = 1459 NA NA NA 
Streetan et al., 2006 Caucasian (Amish), US ped = 48, n = 964 radius 3q26 2.11 
  (men only) total hip 7q31 4.15 
   total hip 12q24 2.6 
   femoral neck 7q31 3.09 
   femoral neck 18p11 2.07 
   spine 21q22 3.36 
  (women only) femoral neck 1p36 2..02 
   spine 1q21 2.11 
  (<50 years) radius 11q32 2.11 
   femoral neck 14q23 2.16 
  (>50 years) spine 3p25 2.32 
Xiao et al., 2006 Caucasian, US ped = 451, n = 4126 wrist 2q32 2.23 
   wrist 5q23 3.39 
   wrist 7p15 2.15 
   hip 2q32 2.11 
   hip 3p14 2.29 
   hip 3q27 2.55 
   spine 3p25 2.09 
  (men only) wrist 1p36 2.81 
   hip 7p12 3.01 
   spine 13q12 2.5 
   spine 13q33 2.96 
  (women only) wrist 3p25 3.31 
   wrist 5q23 2.82 
   wrist 6q24 3.05 
   spine 3p25 2.61 
   spine 15q13 4.49 
Hsu et al., 2007 Chinese, China sibs = 941, n = 3093 femoral neck 7p21 3.68 
   total hip 2q24 3.65 
   total hip 7p21 2.93 
   total hip 16q21 3.14 
   femoral neck 2q24 2.31 
   femoral neck 7p21 3.68 
   femoral neck 16q21 2.9 
      spine 5q21 2.71 
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Table 1.2.  (continued)  
 
Reference Population Sample Trait Region LOD 
Hsu et al., 2007 Chinese, China sibs = 941, n = 3093 whole body 2q31 2.71 
   whole body 7p21 2.47 
   whole body 16q22 2.52 
  (women only) spine 13q21 3.61 
Wang et al., 2007 Caucasian, US ped = 451, n = 4126 P.C. 1 2q32 3.35 
Zhang et al., 2008 Caucasian, US ped = 207, n = 2200 hip 12p12 2.79 
   hip 22q13 2.16 
   wrist 2p13 2.04 
   wrist 10p14 2.31 
   wrist 14q23 2.07 
  (men only) hip 15q26 2.93 
   spine 7p21 2.1 
  (women only) wrist 2p13 2.64 
   wrist 18q21 2.29 
Willaert et al., 2008 Caucasian, Belgium  ped = 1, n = 34 spine 1p36 3.07 
 
ped = number of pedigrees; sib = number of sibships: n = sample size; P.C. = principal component 
 
 
Few of the QTLs identified via linkage analysis have led to the discovery of specific 
genetic variants affecting BMD.  In particular, evidence of linkage on chromosome 11q12, which 
has been identified in several studies (41,46,49), is thought to be due to the low density 
lipoprotein receptor related protein 5 (LRP5) gene.  Two genome-wide linkage scan meta-
analyses have been performed (58,59) showing strongest evidence of linkage to chromosomes 
1p13-q23, 9q31-33 (58), and  16pter-p12.3 (59).   
In addition to linkage analysis scans, a number of association and candidate gene studies 
have also been performed, which implicate specific alleles in osteoporosis and BMD regulation.  
The majority of such studies have focused on genes with reasonable biological connections to 
bone regulation and structure, including collagenic and non-collagenic bone matrix proteins, 
adehesion molecules and ligands, calciotropic hormones/receptors, cytokines, growth 
factors/receptors, metabolic pathways, and sex hormones/receptors (60).  Association and 
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candidate gene studies for BMD and osteoporosis have specifically looked for effects of the 
following (non-exhaustive) list of candidate genes:  estrogen receptor (61-63), vitamin D 
receptor (62-68), collagen type 1 (63,67,69), parathyroid hormone receptor type 1 (63), 
interleukin 6 (63,70-73), tumor necrosis factor-alpha (74,75), calcitonin receptor (68,76,77), 
LRP5 (78), apolipoprotein E (79), osteocalcin (80), insulin-like growth factor (81), alpha 2HS 
glycoprotein (82), and the osteoclast-specific subunit of the vacuolar proton pump (83).  Like 
those of the linkage scans, studies of candidate genes have produced inconsistent results, which 
again may be due to population differences between studies including genetic heterogeneity, 
ancestry, gender, age, menopausal status, and frequencies of polymorphisms.  Additionally, the 
conflicting findings may be due to false positives caused by inappropriately chosen control 
groups, selection bias, or population substructure including admixture (60).  Therefore more 
work is required to conclusively characterize the role of these gene candidates in the regulation 
of BMD. 
Coinciding with the advent of affordable, high-density genotyping platforms for hundreds 
of thousands of single nucleotide polymorphisms (SNPs), genome-wide association studies for 
BMD are currently underway.  One such study using the 100K SNP GeneChip marker set in the 
Framingham cohort found that the majority of the top genetic associations with BMD occurred 
for SNPs in genes that have not been previously studied with regard to bone strength phenotypes 
(84).  This study is the first of undoubtedly many genome-wide scans which will test even 
greater numbers of SNPs in the search for new candidate loci that many affect osteoporosis.    
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1.4 EPIDEMIOLOGY OF LONGITUDINAL CHANGE IN BONE MINERAL 
DENSITY 
Bone is continually being remodeled through the cycle of bone formation and resorption, thus 
changes in bone mass may result from an imbalance of these two processes of bone turnover.  
Observed BMD can therefore be conceptualized as the net result of (i) peak bone mass 
attainment (and maintenance) and (ii) subsequent loss of bone that occurs when resorption 
exceeds formation.  Findings of cross-sectional studies of BMD may be reflective of either of 
these two processes, or both.  However, many cross-sectional studies adjust analyses for age, 
thereby estimating peak BMD, and as a result, findings may pertain less to the process by which 
BMD changes over time, and more to the acquisition of peak BMD.  Longitudinal studies of 
BMD, on the other hand, pertain primarily to the changes in BMD over time.  In the existing 
body of literature, change in BMD has been quantified either as absolute or percent change over 
unit time.   
Previous studies have demonstrated several environmental factors that affect BMD 
change, including baseline weight and interim change in weight, alcohol consumption, smoking, 
female gender, estrogen replacement therapy (85), and menopausal status (86).  Mixed findings 
have been reported for the effects of exercise (85,87), calcium intake, and serum vitamin D level 
(87,88).  Additionally, BMD change during the first year following a hip fracture is as much as 5 
times that reported in the non-fractured population (88).  The magnitude and timing of BMD 
change, and the effects of significant environmental factors, may differ among bone sites (85-
87,89), and may differ between cortical and trabecular bone.  Recent work suggests that 
substantial loss of trabecular bone may begin in the third decade (17,90-92), whereas loss of 
cortical bone may occur primarily in later life (17,91,92) in both sexes; however, the exact 
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timing of onset of age-related BMD change is largely uncertain.  Estimates of rate of change 
derived from cross-sectional data are inconsistent with  rate of change obtained from longitudinal 
data for forearm, hip (89), spine (86,89) and whole body (86) BMD. These results emphasize the 
need for longitudinal data to appropriately study the process of age-related decline in BMD. 
Previous work comparing BMD change in older African American and Caucasian men 
(14), and women (8) show that Caucasians experience a greater decline in BMD over time than 
African Americans.  These racial differences suggest that underlying genetic factors may 
influence change in BMD, which is discussed in the following section.  Previously, no 
longitudinal studies have looked at BMD change in Mexican Americans. 
1.5 GENETICS OF LONGITUDINAL CHANGE IN BONE MINERAL DENSITY 
To date, very few studies have addressed the role of genetic factors in change in bone traits over 
time, and all of them have been limited to the same approach:  estimating heritability of bone 
loss in twins/siblings.  No linkage or genetic association studies have yet been performed for 
longitudinal change in bone phenotypes. 
The National Heart, Lung and Blood Institute Twin Study, which included 25 
monozygotic, and 21 dizygotic pairs of Caucasian male twins (45-55 years of age), was the first 
study to look at heritability of BMD change.  Radial bone mass and BMD were measured at 
baseline, and again 16 years later.  The findings of this study provide little evidence for 
heritability of change in BMD.  Intraclass correlations for monozygotic twins (rMZ) and 
dizygotic twins (rDZ) were 0.52 and 0.49, respectively, for absolute change in radial bone mass, 
and 0.35 and 0.43, respectively, for absolute radial BMD change.  While both rMZ and rDZ for 
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change in bone mass and BMD change were significantly greater than 0, they were similar in 
magnitude indicating that the correlations were not due to genetic factors.  Heritability (h2), 
which was approximated as twice the difference between rMZ and rDZ, was 0.06 and -0.15 
(neither is statistically significant), respectively, for changes in bone mass and BMD (26). 
This study design had several limitations that may have resulted in its failure to detect 
heritability of BMD change.  Because the sample sizes were small, and less than 60% of the 
pairs measured at baseline were available at follow-up, this study was underpowered to detect 
modestly sized genetic effects.  Also, the role of environmental covariates, which may have 
largely impacted the observed change in bone phenotypes, was not considered in calculations of 
either intraclass correlations or heritability.  Adjusting for covariates is especially important for 
older twins who may have differentially accumulated environmental insults affecting bone 
phenotypes over the 16 years between measurements.  Failure to do so may have masked genetic 
effects in an already underpowered study.   
A second study in 21 mono- and 19 dizygotic twins (ages 24-75, both sexes) reported 
stronger evidence for the heritability of change in bone traits over 1.1 to 5.5 years.  Estimates of 
rMZ and rDZ were 0.93 and 0.51, respectively, for annualized percent change in lumbar BMD, 
and 0.60 and 0.11, respectively, for annualized percent change in Ward’s triangle (93).  This 
study was the first to report statistically significant results despite small sample sizes and failure 
to consider environmental factors.  The magnitude of the genetic effect on change in BMD 
demonstrated in this study may be inflated due to the study design—differences in the relative 
environments of mono- and dizygotic twins may have led to exaggerated heritability.  Moreover, 
twins across a broad range of ages were included, muddling the interpretation of these results, 
since the rates of BMD change are known to vary with age.  
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Very recently, two larger studies in premenopausal (94) and peri- and postmenopausal 
(95) women have convincingly established that BMD change, at least in some populations and 
for some skeletal sites, is heritable.  Hui et al., estimated that the heritability (h2) of 5.7-year 
BMD change of the femoral neck in 388 Caucasian sisters (20-50 years of age from 178 
sibships) was 0.35 to 0.40 (94).  A complimentary study in 724 older female twins (177 mono- 
and 185 dizygotic pairs, ages 45 to 82 years) showed 4.9-year change in BMD was heritable for 
the spine (h2 = 0.38), total forearm (h2 = 0.49) and whole body (h2 = 0.44), but not skeletal sites 
of the hip (95).  These investigations were superior to the previous twin studies due to their 
larger sample sizes and adjustment for environmental covariates affecting BMD change.  
However, many questions remain, such as whether BMD change is heritable in men and non-
Caucasian women, whether heritability or genetic correlation differs between younger and older 
cohorts, and whether genes influencing BMD change differ from those affecting peak BMD 
attainment or between skeletal sites.   
In summary, few studies have been done to quantify or identify genetic factors affecting 
change in bone phenotypes.  Certainly major barriers to this type of research are the logistics and 
expense of longitudinal, family-based study designs.  Nevertheless, a growing body of 
knowledge indicates that change in bone over time may be due to genetic factors.  More work is 
needed to clearly establish the heritability of BMD change, opening the way for investigation of 
more interesting questions regarding the genetics of BMD change, such as identifying linked 
chromosomal regions, associated polymorphisms, and gene × environment interactions. 
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1.6 THE SAN ANTONIO FAMILY OSTEOPOROSIS STUDY 
The San Antonio Family Osteoporosis Study (SAFOS) was started in 1997 with the goal of 
studying the environmental and genetic determinants of bone strength-related phenotypes.  As an 
ancillary to The San Antonio Heart Study (SAFHS) (96), recruitment for SAFOS was held in 
conjunction with the follow-up phase of SAFHS.  Probands of Mexican American ancestry were 
identified in a low-income neighborhood of San Antonio, and all first-, second-, and third-degree 
relatives of probands and spouses were invited to participate irrespective of medical history.  
Inclusion criteria for probands stipulated only that they be 40 to 60 years of age with large 
extended families in the San Antonio area.  Body composition data measured by dual-energy x-
ray absorptiometry (DXA) was collected for 895 unselected Mexican Americans from 34 
multigenerational families.  An example pedigree is shown in Figure 1.1.  Eleven individuals 
were excluded from the study due to use of corticosteroids and aberrant DXA measurements, 
thus the total sample size for this study is n = 884.  Data on numerous demographic, 
anthropologic, medical, reproductive, and lifestyle traits were collected, as well as DNA samples 
used for the genotyping of 460 highly-polymorphic microsatellite markers.  To date, the SAFOS 
has yielded numerous insights into the genetic causes and environmental correlates of variation 
in BMD.   
 
 
Figure 1.1.  Sample pedigree.  Arrow indicates proband.  Data are available on shaded individuals 
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The co-morbidity of osteoporosis and atherosclerosis was explored by Kammerer et al. 
(97), in which the association between BMD and intimal medial thickness (IMT) of the carotid 
artery (i.e. a measure of pre-clinical atherosclerosis) was reported in female SAFOS participants 
(p < 0.05 for hip, spine, and forearm skeletal sites).  Associations were also observed for a 
polymorphism of the vitamin D receptor gene (VDR) with both IMT and BMD (of the spine and 
forearm, but not hip), though BMD did not account for the relationship between IMT and VDR 
(97).  This work was followed-up by Shaffer et al., who reported the association between IMT 
and forearm BMD in men, and showed that serum lipid traits and markers of inflammation (i.e. 
known risk factors for atherosclerosis) did not mediate the relationship between BMD and IMT 
in men and women (98).     
Heritability and effects of environmental determinants of BMD were previously assessed 
separately for men and women in the SAFOS sample.  Mitchell et al. (30) estimated that the 
heritable component of common variation in BMD was 0.22 to 0.62 in men, and 0.20 to 0.56 in 
women for skeletal sites at the hip, spine, and forearm.  The total proportion of BMD variation 
explained by environmental correlates (i.e. age, age2, diabetes, education, smoking, alcohol 
consumption, physical activity, dietary calcium, supplemental calcium intake, body mass index, 
menopause, oral contraception, hormone replacement therapy, parity, breastfeeding) was 0.05 to 
0.47 in men and 0.26 to 0.46 in women (30). 
Motivated by the high heritability of BMD phenotypes in this population, linkage 
analysis was undertaken in a subset (n = 664, approximately 75% of the total sample for whom 
genotype data were available) of the SAFOS population using 416 microsatellite markers (9.5 
cM mean resolution) to identify specific genomic regions influencing BMD.  Kammerer et al. 
(42), reported significant (99) QTLs on chromosome 4p for forearm BMD (logarithm of the 
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odds, LOD = 4.33), chromosome 2p for femoral neck BMD in men (LOD = 3.98), and 
chromosome 13q for trochanter BMD in men (LOD = 3.46).  Suggestive evidence of linkage was 
also observed on chromosome 6q for trochanter BMD (LOD = 2.27), chromosomes 7q and 12q 
for forearm BMD (LOD = 2.24 for both), chromosomes 8p and 13q for femoral neck BMD in 
men (LOD = 2.15 and 2.51, respectively), and chromosome 20 for forearm BMD in women 
(LOD = 2.18) (42).   
Investigation of the strong QTL on chromosome 4p for forearm BMD was continued by 
Chaney et al. (100) via genetic association testing of promising positional candidate genes in the 
region.  Polymorphisms in one such gene, fibroblast growth factor binding protein 1 (FGFBP1), 
which had not previously been studied with regard to osteoporosis, showed strong association 
with BMD.  These findings were replicated in an independent population (Amish), and 
functional studies revealed that three polymorphisms in FGFBP1 were associated with decreased 
gene expression in vitro.  However, polymorphisms in FGFBP1 did not account for the linkage 
signal, therefore high density SNP genotyping covering the remaining genes in this region was 
carried out to search for other candidate genes.  Polymorphisms in four additional genes in this 
region showed association to BMD, but they did not account for the linkage signal in the SAFOS 
population.  Because genotype coverage of this region was not complete, one or more un-typed 
polymorphisms may account for the QTL on chromosome 4p (100).    
The follow-up phase of SAFOS began in 2003 with the reenrollment of 724 (81%) 
participants from the original sample in addition to 163 new participants from the SAFOS 
families (total follow-up sample, n = 887).  Body composition and covariate measurements were 
again collected (approximately 5 years after initial measurements) and genotyping for all 
participants was completed.   
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1.7 OVERVIEW OF ANALYTICAL METHODS  
The principal methodologies used in this dissertation research are described below.  These 
methods have been used to investigate the questions enumerated in Section 1.8.  
1.7.1 Cross-sectional analysis of longitudinally-assessed measures 
A major focus of this dissertation was to explore the genetic and environmental determinants of 
longitudinally-assessed change in BMD, which was calculated from BMD measured at two time-
points.  While we utilized a longitudinal study design to collect data on BMD change over time, 
we did not employ longitudinal analytical methods in this dissertation.  Instead, we analyzed 
BMD change as a single metric, thus, this project is essentially a cross-sectional investigation of 
a longitudinally-assessed trait.  In the following chapters we use the terms "cross-sectional" and 
"longitudinal" to reflect how the phenotype of interest was measured (e.g. baseline BMD is a 
cross-sectional measurement whereas BMD change is a longitudinal measurement), rather than 
how the data were analyzed.    
1.7.2 Metric for BMD change 
We calculated and performed analyses on two metrics of BMD change:  (i) annualized absolute 
change in BMD (mg/cm2/year) defined as the difference between follow-up and baseline BMD 
measurements divided by the exact elapsed time between measurements and (ii) annualized 
change in standardized BMD (%SD/year) defined as 100% times the difference between 
independently standardized (mean = 0, SD = 1) measurements of follow-up and baseline BMD 
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divided by the exact elapsed time between measurements.  The latter metric, which was adopted 
to prevent possible bias due to differences in densitometry at the two time points, retains only 
information about the variance of BMD change (not the magnitude).  Results of analyses for 
these two metrics showed excellent agreement; therefore we present results for only one of them.  
In Chapter 3 we show results for annualized absolute change in BMD and, in response to 
reviewers' concerns, state that results for annualized change in standardized BMD were nearly 
identical.  In Chapter 4 we show results for annualized change in standardized BMD. 
Another metric commonly used to quantify change in BMD in other studies is yearly 
percent change in BMD (%/year) defined as 100% times the annualized absolute change divided 
by baseline BMD.  We do not present results of analyses for this metric.  However, results from 
preliminary analyses of percent BMD change on data from a subset of 609 individuals 
(conducted while follow-up data collection was still underway) were very similar to those for 
annualized absolute change.   
1.7.3 Covariate selection 
The effects of a large number of environmental and endogenous covariates were originally 
considered in this project (Table 1.3).   As described below, different procedures were used to 
select covariates for analyses of longitudinally-assessed BMD change in (i) older and (ii) 
younger individuals, and (iii) cross-sectional BMD at baseline and follow-up.  These differing 
procedures resulted from the availability and comparability of  covariate data among the 
different groups, however, after identifying a set of possibly-significant covariates, all covariates 
were assessed within the variance component framework (described in Section 1.7.4) allowing 
for non-independence of observations.   
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Table 1.3.  Environmental and endogenous covariates considered in this study 
demographic anthropometric reproductive medical lifestyle 
sex height baseline menopause diabetes physical activity 
age change in height follow-up menopause hypertension smoking 
age2 weight interim menopause  alcohol consumption 
sex × age change in weight oral contraceptives  calcium supplement 
sex × age2 body mass index  parity  calcium intake 
 change in body mass index months of breastfeeding  education  
  baseline BMD hormone replacement therapy     
 
 
Environmental determinants of BMD change were initially assessed in a sub-sample of 
609 individuals while follow-up data collection was still underway.  Bi-directional stepwise 
multiple regression analysis, while ignoring the familial dependency of the observations, was 
used to determine suites of covariates with possible effects on BMD change based on Akaike 
Information Criterion.  Such analyses may result in inflated significance of covariate effects.  
Based on these preliminary analyses, several possible covariates were excluded from future 
consideration, such as parity, oral contraceptives, breastfeeding, hormone replacement therapy, 
hypertension, physical activity, smoking, alcohol consumption, use of calcium supplements, 
calcium intake, and education.   The remaining covariates, including sex, age, age2, sex × age, 
sex × age2, baseline BMD, weight, change in weight, height, change in height, body mass index, 
change in body mass index, baseline menopause, and follow-up menopause, were re-evaluated 
via bi-directional stepwise multiple regression (again, while ignoring family structure) in the 
total sample after follow-up data collection was completed.  Because weight and body mass 
index are highly correlated, these covariates were included one-at-a-time in regression models 
and whichever explained more phenotypic variation was retained.     
For simplicity, covariates showing effects on BMD change in stepwise regression 
analyses in older individuals for one or more skeletal sites were forced into the final variance 
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components models presented in Chapter 3.  This suite of covariates includes sex, age, age2, sex 
× age, sex × age2, baseline BMD, weight, change in weight, change in height, baseline 
menopause, and follow-up menopause.   
A different covariate selection procedure was used for BMD change in younger 
individuals (Chapter 4).  Covariates identified via stepwise regression in the total sample were 
tested within the variance components framework (which considers the pedigree structure of the 
data) and retained if statistically significant at a liberal threshold of α = 0.1 on a skeletal site-
specific basis. 
Another covariate selection procedure was used in analysis of baseline and follow-up 
BMD (Chapters 5 and 6).  Environmental determinants of baseline BMD have been previously 
reported (30).  However, not all covariates were reassessed at follow-up.  Because a major focus 
of this project was to compare cross-sectional analyses of baseline and follow-up BMD, we 
limited our possible suites of covariates to those assessed at both time points (i.e. sex, age, age2, 
sex × age, sex × age2, body mass index, menopause, oral contraceptives, diabetes, smoking, 
alcohol consumption, and supplemental calcium intake). Covariates identified via stepwise 
regression in the baseline and follow-up samples were tested within the variance components 
framework and retained at the threshold of α = 0.1 on a skeletal site-specific basis.   
1.7.4 Variance components analysis 
In this dissertation, the environmental and genetic determinants of BMD and change in BMD 
were modeled within a variance components framework using the Sequential Oligogenic 
Linkage Analysis Routines (SOLAR) software (101).  In brief, this methodology partitions the 
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total phenotypic variance into environmental, genetic (i.e. polygenic and QTL), and error 
components.  The variance model takes the general form:  
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where  is the total phenotypic variance,  is the environmental component,  is the 
genetic component, and  is the error component.  In this model, the environmental component 
encompasses the variance due to the effects of measured covariates.  The genetic component 
may be further partitioned into two components:  (i) a QTL component, , which is based on 
genetic sharing identity-by-decent (IBD) at an arbitrary chromosomal position as estimated from 
genotyped markers via a Markov Chain Monte Carlo algorithm implemented in Loki (102), and 
(ii) a residual heritable component, , also called the polygenic component, which is based on 
the expected genetic sharing between relatives and comprises the variance attributable to all 
additive genetic loci excluding that due to the QTL component (if any).  The polygenic 
component is used to estimate the two measures of phenotype heritability considered in this 
dissertation:  (i) the narrow-sense heritability, h
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and (ii) the residual heritability, h2r, which is calculated as the ratio of the polygenic component 
to the residual phenotypic variance after removing the environmental component: 
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Since both of these measures of heritability are used as indicators of the cumulative amount of 
variance explained by all additive genetic loci, they are assessed only for models lacking the 
QTL component (i.e., under the constraint = 0).  The residual error component, , includes 
all variance not modeled by the other components, including non-additive genetic variance, 
unmeasured environmental variances, and other sources of error variance.   
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The aforementioned components of phenotypic variance are generated by modeling the 
phenotype as follows:  
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where μ is the overall mean of the trait,  Xij is the jth covariate for the ith individual, βj is the 
corresponding regression coefficient, gi is the additive genetic effect, mi is the effect of an 
arbitrary QTL, and ei is the residual error effect.  Pedigree-based maximum likelihood methods 
are used to estimate these parameters, and their significance is assessed via the likelihood ratio 
test, which compares the full model (i.e., containing the parameter to be tested) to the nested 
model (i.e., constraining the parameter to be tested).  The test statistic asymptotically follows the 
chi-squared distribution with 1 degree of freedom for testing covariates (H0: βj = 0), and follows 
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a 50:50 mixture of chi-squared distribution with 1 degree of freedom and a point mass at zero for 
testing heritability (H0: h2 = 0) and linkage (H0:  = 0).  The proportion of total variance 
attributable to covariate effects is assessed by comparing the estimated variance in the model 
excluding all covariate effects to that of the model including them.   
2
mσ
1.7.5 The LOD score 
Evidence of linkage, modeled by the QTL component, , is assessed at 1 cM intervals across 
the genome.  By tradition, the statistical significance of  is reported as a LOD score (log
2
mσ
2
mσ 10 of 
the likelihood ratio), and according to guidelines set by Lander and Kruglyak (99), the LOD 
thresholds for determining suggestive and significant evidence of genome-wide linkage are LOD 
= 1.9 and 3.3, respectively.  In this dissertation, we have used LOD > 2.0 to indicate suggestive 
linkage.  Due to the limited number of recombination events occurring in the sample pedigrees, a 
putative QTL cannot be mapped to an exact chromosomal position, and need not occur directly 
at the maximum LOD score.  Instead, a QTL can be mapped to a general chromosomal region.  
In this dissertation we have explored the one-LOD unit support interval (which is the region 
surrounding a linkage peak with boundaries occurring at the chromosomal positions exhibiting 
evidence of linkage equal to 1 unit less than the maximum LOD score) for positional candidate 
genes.  The one-LOD unit support interval, originally recommended by Conneally et al. (103) is 
used in this dissertation as a rule-of-thumb for defining a linkage region, rather than a 
statistically rigorous confidence interval. 
The variance components methods used to assess linkage assume multivariate normality 
of the phenotype, and deviations of the phenotype distribution from multivariate normality have 
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been shown to cause excessive Type I error (104).  Therefore empirical LOD score adjustment 
based on 10,000 simulations of a fully-informative, unlinked marker was used to estimate a 
linear LOD score adjustment factor to guard against inflated LOD scores.  Simulations have 
shown such adjustment adequately yields robust LOD scores (104).   
 
1.7.6 Testing unequal genetic variances between subsets 
One of the major hypotheses explored in this dissertation is whether the roles of genes on bone 
phenotypes of interest may differ between two groups, for example, between men and women, or 
between younger and older individuals.  We have used an extension of the general variance 
components framework described above that allows genetic variances (i.e. polygenic 
components, ) to differ between two groups when both are analyzed simultaneously.  Details 
for this method have been described previously for modeling separate genetic variance in men 
and women (25) and pre- and postmenopausal women (24).  In brief, the expected additive 
genetic covariance between two relatives, i and j, from different groups, A and B, is defined as: 
2
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COV(Ai,Bj) = gBgAg σσρ ××Φ2 , 
 
where Φ is the kinship coefficient between the two relatives, ρg is the additive genetic correlation 
between groups A and B, σgA is the genetic standard deviation in group A, and σgB is the additive 
genetic standard deviation in group B.  The genetic correlation quantifies the degree to which the 
additive genetic variation among members of group A correlates with the additive genetic 
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variation among members of group B.  These additional parameters allow the phenotypic 
variance to be partitioned into group-specific heritable components,  and , along with 
group-specific residual error terms,  and .  The environmental component, , is 
modeled exactly as in the general variance components framework detailed above.  Covariates 
are assumed to have common marginal effects on both groups; group-specific covariate effects 
are modeled as interactions with a dummy variable indicating individuals' membership in a 
group. 
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This expanded model was used to test two specific hypotheses regarding the role of genes 
in the two groups:  (i) whether the group-specific additive genetic variances are equal (H0:   
= ) , and (ii) whether the additive genetic correlation between groups was different than one 
(H
2
eAσ
2
eBσ
0:  ρg = 1).  Unequal additive genetic variances would imply that genes account for more 
phenotypic variation in one group than the other.  Inter-group genetic correlation significantly 
less than 1 would imply that partially different suites of genes are contributing to BMD variation 
in groups A and B.  A genetic correlation equal to zero would imply that different genes 
influence the trait in each group.  Pedigree-based maximum likelihood methods were used to 
estimate model parameters.  The likelihood ratio test was used to test for unequal additive 
genetic variances by comparing the full model (where parameters , , and ρ2eAσ 2eBσ g are 
estimated) to a constrained model (where  = ), which asymptotically follows the chi-
square distribution with 1 degree of freedom.  The likelihood ratio test was also used to test for 
genetic correlation less than 1 by comparing the full model to a constrained mode (where  ρ
2
eAσ 2eBσ
g = 
1), which asymptotically follows a 50:50 mixture of a point mass at zero and a chi-squared 
distribution with 1 degree of freedom. 
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This modeling framework was utilized in Chapter 2 to test for unequal genetic variances 
in bone loss phenotypes between individuals younger and older than 45 years.  In Chapter 5 this 
methodology was used to test for sex-specific additive genetic effects on cross-sectional BMD.    
1.8 QUESTIONS WE EXPLORED  
In this dissertation we investigated the longitudinal aspects of SAFOS to better understand the 
risk factors for osteoporosis.  Research was conducted under the risk model (Figure 1.2) that 
bone strength and risk of osteoporosis-related heath outcomes are determined by the genes and 
environmental factors influencing peak BMD attainment in youth, and by the genes and 
environmental factors affecting subsequent loss with age.  A number of questions regarding the 
roles of such genetic and environmental determinants of osteoporotic risk were explored in this 
project.   
 
 
Figure 1.2.  Risk model for osteoporosis 
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In Chapter 2 we introduce change in BMD as a quantitative trait, and ask how the rate of 
BMD change differs over the adult lifespan in Mexican Americans:  At what age do involutive 
changes in BMD occur?  Is the trajectory of BMD over time similar across skeletal sites and 
between men and women?  Could distinct genes be acting on rates of BMD change at different 
ages?    
Next, we investigated the roles of genetic and environmental factors on longitudinal 
change in BMD:  What measured covariates have significant effects on rate of BMD change?  Is 
rate of BMD change heritable?  What specific chromosomal regions influence rate of change?  
Chapters 3 and 4 (formatted for journal publication) explore these questions in older (>45 years) 
and younger (<45 years) sub-samples of the SAFOS population. 
We also examined cross-sectional measures of areal BMD at baseline and follow-up to 
examine the roles of environmental and genetic factors on peak BMD.  Specifically, we asked:  
Do analyses of baseline and follow-up data show similar heritability and effects of covariates for 
hip and spine BMD, both overall and within the sexes?  Are chromosomal regions influencing 
peak BMD observed at both time points?  How does the concordance or discordance of results 
between baseline and follow-up affect interpretation of our findings?  These questions are 
examined in Chapters 5 and 6 (formatted for journal publication).   
This dissertation concludes with a discussion of our major findings and their implications 
for osteoporosis.  In particular, we pull together results from the preceding chapters to address 
the questions of whether chromosomal regions influencing peak BMD overlap with those 
affecting bone loss and whether genes controlling early bone loss are distinct from those 
affecting late bone loss.  These questions, along with future directions for the study of 
osteoporotic risk and the public health implications of this work are addressed in Chapter 7.     
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2.0  AGE-RELATED CHANGES IN BONE METABOLISM 
2.1 INTRODUCTION 
Skeletal growth occurs jointly with linear bone mineral density (BMD) accrual during youth.  By 
age 20, adult skeleton size is usually achieved, followed by a period of bone consolidation 
lasting up to 15 years where BMD accretion continues, but skeletal size remains static (105).  
The exact timing of peak BMD acquisition is unknown and likely differs between skeletal sites, 
individuals, sexes, and populations (106).  During the period leading up to peak attainment, 
change in BMD results from two processes:  bone modeling (i.e. where bones are shaped through 
independent processes of bone deposition and removal) and bone remodeling (a.k.a. bone 
turnover, where bone resorption and formation are tightly coupled in a cycle of bone renewal) 
(107).  Most cross-sectional studies indicate that peak BMD is achieved sometime during young 
adulthood followed by a prolonged plateau phase where BMD is maintained with little or no 
change (106).  Other studies show varying degrees of bone loss occurring immediately after peak 
attainment, particularly in trabecular bone (17,92).  Unlike changes leading up to peak BMD, 
most age-related changes in BMD after peak attainment are the result of imbalanced bone 
turnover, where more bone is formed than is resorbed (leading to increased BMD) or more bone 
resorbed than is formed (leading to bone loss) (107).  Over time, bone remodeling also alters the 
geometry of bones, including their size, which in turn affects measurement of BMD (107).  
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Nevertheless, change in BMD in adults is largely an outcome of bone turnover, thus measuring 
change in BMD serves as indicator of bone metabolism. 
Age-related bone loss occurs at all skeletal sites; however, like peak BMD acquisition, 
the timing of onset of bone loss is not entirely clear (108,109), and certainly differs by skeletal 
site, sex, and population, and may be delayed or hastened by environmental factors.  During 
menopause, changes in hormone production result in increased bone resorption and concurrent 
decline in BMD, especially in trabecular bone (110).  Rapid bone loss occurring in late stages of 
life has been documented in numerous studies (111).   
Over the course of the lifespan, the relationship of BMD with age exhibits (at least) three 
distinct phases:  initial increase in BMD in adolescents leading to peak BMD in young adults, 
stabilization of BMD at maturity, and decline in BMD in postmenopausal women and the elderly 
(109,112).  Because measurable BMD in older individuals is the net result of all three of these 
phases, we hypothesize that osteoporosis later in life is due in part to the processes that affect 
BMD across the entire lifespan.   
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 Figure 2.1.  Mean total hip BMD (g/cm2, binned by decade) by age in SAFOS men (blue squares, blue line) and 
women (red circles, red line) 
 
 
 
Figure 2.2.  Mean total hip BMD (g/cm2, binned by decade) by age in Mexican American men (blue solid squares, 
blue solid line) and women (red solid circles, red solid line) and Caucasian men (blue open squares, blue dashed 
line) and women (red open circles, red dashed line) in NHANES III (18) 
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2.2 INVOLUTIVE BONE CHANGE OCCURRING IN MIDLIFE  
The apparent trajectory (based on cross-sectional data) of mean total hip BMD with age (binned 
by decade) in the San Antonio Family Osteoporosis Study (SAFOS) sample is shown in Figure 
2.1.  For comparison, the apparent trajectory (based on cross-sectional data) of mean total hip 
BMD in Caucasian and Mexican American participants of the National Health And Nutrition 
Examination Survey (NHANES III) is shown in Figure 2.2 (18).  Looking cross-sectionally, the 
apparent trend in BMD over time shifts sometime during the fifth decade (at approximately 45 
years of age), in men and women of SAFOS and NHANES. 
The age at which involutive bone changes occur (i.e. the inflection point of BMD) was 
investigated in an extensive study by Malkin et al., (109) who collected BMD measurements in 
4945 adult subjects (2430 men and 2515 women aged 18 to 100 years) from 5 ethno-
geographical populations.  The sex-specific age dependence of BMD was assessed by fitting 
many models (i.e. BMD as a mathematical function of age) using maximum likelihood methods.  
Models investigated included polynomial (zeroth through 4th power), exponential, logarithmic, 
and logistic functions, as well as piecewise combinations of constant and linear functions (i.e. 
two different functions applied to BMD data of participants younger and older than some age 
parameter).  Akaike Information Criterion and likelihood ratio tests of nested models were used 
to determine the most parsimonious model and assess the significance of parameters.  Piecewise 
combination models were best for women in all 5 ethno-geographic groups and for men in 4 of 
the 5 ethno-geographic groups (109). 
Malkin et al. found that the exact age at inflection varied by sex and population from 28 
years to 48 years (Table 2.1).  Statistically significant pair-wise differences in the timing of 
involution were observed between most ethno-geographic groups for both men and women.  In 
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particular, Asian men and women experienced a change in BMD trend at 34 and 43 years of age, 
respectively, whereas Caucasian men and women underwent this change at 49 and 44, 
respectively.  These results are consistent with observations in our SAFOS sample, especially if 
we consider that Mexican Americans are an admixed population with of large proportions of 
Caucasian and Amerindian (Asian) ancestry, and that ages of inflection in Mexican American 
men and women may fall somewhere between those of the parent populations.  Environmental 
differences between populations may also affect the onset of involutive bone changes.   
 
 
Table 2.1.  Age of involutive BMD changes as modeled by Malkin et al. in five ethno-geographic populations (109) 
 
  Age at involution (years) 
Population Men Women 
Slavic 34 40 
Asian 34 43 
Turkmenian   -  38 
Caucasian 49 44 
Chuvasha 28 48 
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Figure 2.3.  Baseline and follow-up BMD (g/cm2) by age for total hip, ultradistal radius, and total spine in men (blue Xs) and women 
(red circles).    Local regression (LOWESS) curves are shown for the total sample (black), men (blue), and women (red). 
 
 
34 
 Figure 2.4.  Annual change in BMD (mg/cm2/year) by baseline age for total hip, ultradistal radius, and total spine in men (blue Xs) and women (red 
circles).  Local regression (LOWESS) curves are shown for the total sample (black), men (blue), and women (red). 
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Figure 2.3 plots unadjusted BMD data for SAFOS baseline and follow-up samples and 
fits local regression (LOWESS) curves to represent the trend with age.  Strictly speaking, the 
search of model-space as employed by Malkin et al. is not appropriate for our family-based 
SAFOS sample.  However, the shift in trend of BMD over time (occurring between age 40 and 
50 years) is apparent.  Age of involution for baseline BMD measurements occurs at 
approximately 45 years for total hip, 43 years for ultradistal radius, and 45 years for total spine.  
Involution occurred at similar ages for follow-up BMD measurements .  Note that the trend of 
spine BMD with age in older men appears inconsistent with bone loss.  This phenomenon is 
possibly an artifact of inflated densitometry measurements of spine in men due to the high 
prevalence of osteoarthritis (resulting in growth of osteophytes, i.e. boney spurs) and aortic 
calcification in this age group (113-115).  Figure 2.4 plots the annual change in BMD between 
baseline and follow-up measurements by age, with trends indicated by LOWESS regression 
curves.  Looking longitudinally, again, the shift in trend of rates of BMD change over time is 
apparent between the fifth and sixth decades (at approximately 45 years of age).  These 
observations are consistent with recent work exploring the timing of onset of loss in trabecular 
and cortical bone:  cortical bone, in particular, undergoes a characteristic involutive shift midlife 
(17,92).   
2.3 GENETICS ANALYSIS OF BMD ACROSS AGE RANGES 
Genetic analyses of BMD, such as heritability and linkage studies, have generally focused on 
peak BMD, and when necessary have made linear and/or quadratic adjustment for age to model 
peak BMD.  One problem with this approach is that it assumes a universal trajectory of BMD 
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over the lifespan and may lead to a loss of important data with respect to inter-individual 
variation in trajectory (109).  In other words, such age-adjustment assumes that the rates of 
change in BMD over time are identical for all individuals; however, recent work has suggested 
that variation in rates of change in BMD are under genetic regulation (94,95,116).  Therefore, 
this approach is not ideal.   
The problem of analyzing data across a wide range of ages is even greater if the 
phenotype of interest is rate of BMD change over time.  In this situation there is no reference 
point analogous to cross-sectional peak BMD, so the interpretation of change in BMD depends 
largely on the age range of the sample.  In fact, analysis of BMD change data for samples that 
span multiple phases of BMD progression (i.e. peak acquisition in youth, stabilization at 
maturity, and decline with advanced age) is problematic, and interpretation uncertain.   
Because bone metabolism changes with age, it is likely that different genes may 
influence changes in BMD across the lifespan.  Indeed, activation, deactivation, and changes in 
the regulatory roles of genes may be responsible for some of the changes in bone metabolism 
across the lifespan.  Moreover, there is no evidence that change in BMD at one point in life is 
predictive of change decades later.  Thus, change in BMD as a measure of bone remodeling may 
constitute different "phenotypes" at the metabolic level during different phases of BMD 
progression.  Therefore, the question of how to appropriately analyze family data in order to 
detect genetic effects, which may differ across individuals of different ages, becomes imperative 
to the success of a study.  One option is to jointly model the genetic effects on multiple aspects 
of phenotype trajectory over time (e.g. separate parameters for trends before and after some age 
parameter).  Results of a segregation analysis of cortical index (a measure of cortical thickness, 
which is related to BMD and shows similar age-dependency), by Karasik et al. indicated that (i) 
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baseline level, (ii) age at onset of involutive bone changes, and (iii) rate of decrease with age, are 
all under joint genetic regulation (108).  One problem with this model is that it assumed all three 
parameters describing cortical index (i to iii) were under pleiotropic control by the same genetic 
factor.  While this may be the case for cortical index, it may not be true for other phenotypes; 
instead, it is reasonable to consider that different genes may be involved in these three model 
parameters.   
 
Table 2.2.  Tests for difference in genetic variance between participants <45 and >45 years of age 
 
  genetic SD (mg/cm2/year)   
  <45 years >45 years p-value 
total hip 2.7 8.6 0.02 
ultradistal radius 3.1 5.4 0.04 
total spine 2.8 5.4 0.49 
 
 
Another option to reduce age-related genetic heterogeneity is to limit analysis to age 
ranges representing specific phases of bone metabolism.  For example, separate analyses may be 
carried out for sub-samples younger and older than the age of onset of involutive bone changes.  
We tested whether this approach was sensible in the SAFOS population by modeling genetic 
variance (i.e. the variance due to additive genetic factors) with separate parameters for 
participants younger and older than 45 years.  Pedigree-based maximum likelihood methods 
within a variance components framework were used to estimate parameters of age-specific 
genetic variance, σ2G(<45yr) and σ2G(>45yr).  Details of this method have been described elsewhere 
(24,25).  Statistical significance of the difference in genetic variance between subsets <45 and 
>45 years was assessed via the likelihood ratio test comparing the model with unequal genetic 
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variances to the model with equal genetic variances: σ2G(<45yr) = σ2G(>45yr).  This test statistic 
follows a chi-squared distribution with 1 degree of freedom.  Modeling was performed using the 
Sequential Oligogenetic Linkage Analysis Routines (SOLAR) software (101).  Significant 
differences in genetic variance for participants <45 and >45 years of age were observed for the 
total hip and ultradistal radius, but not the total spine (Table 2.2). 
2.4 CONCLUSIONS 
Several lines of evidence indicate that bone metabolism changes over time, with at least three 
distinct phases (i.e. acquisition, stabilization, and age-related decline) occurring during the 
adolescent and adult lifespan.  However questions remain regarding when these changes occur, 
and the reasons for them.  We hypothesize that genetic factors may be involved in different 
capacities during different phases of bone metabolism.  This assertion is supported by statistical 
modeling of the age-dependency of BMD showing that distinct trends over time occur during 
different stages of life (109).  Such trends are apparent whether looking at cross-sectional or 
longitudinal BMD data in the SAFOS population.  Moreover, recent work indicates that the 
metabolism of the two types of bone, trabecular and cortical, show independent changes over 
time (17,92).  Lastly, genetic modeling of SAFOS participants <45 and >45 years reveals 
statistically significant differences in the magnitude of additive genetic variance for younger and 
older cohorts.   
Altogether, these observations suggest that genetic heterogeneity with regard to BMD, 
and in particular, the rate of change in BMD over time, may exist between phases of bone 
metabolism.  Our hypothesis, which is that variation in BMD and rate of BMD change over time 
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is due, in part, to the effects of separate genes acting on bone metabolism in younger and older 
individuals, was explored by performing separate analysis in individuals <45 and >45 years of 
age.  Results from these analyses, detailed in Chapters 3 to 6, support this hypothesis for change 
in BMD.  While questions still remain, we believe the SAFOS study has made important 
contribution to our understanding of the genetic, as well as environmental, determinants of BMD 
and bone loss.   
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3.1 ABSTRACT 
The genetic contribution to age-related bone loss is not well understood.  We estimated that 
genes accounted for 25-45% of variation in 5-year change in bone mineral density in men and 
women.  An autosome-wide linkage scan yielded no significant evidence for chromosomal 
regions implicated in bone loss.   
 
Introduction:  The contribution of genetics to acquisition of peak bone mass is well 
documented, but little is know about the influence of genes on subsequent bone loss with age.  
We therefore measured 5-year change in bone mineral density (BMD) in 300 Mexican 
Americans (>45 years of age) from the San Antonio Family Osteoporosis Study to identify 
genetic factors influencing bone loss. 
 
Methods:  Annualized change in BMD was calculated from DXA measurements taken 5.5 years 
apart.  Heritability of BMD change was estimated using variance components methods and 
autosome-wide linkage analysis was carried out using 460 microsatellite markers at a mean 7.6 
cM interval density.  
 
Results:  Rate of BMD change was heritable at the forearm (h2r = 0.31, p = 0.021), hip (h2r = 
0.44, p = 0.017), spine (h2r = 0.42, p = 0.005), but not whole body (h2r = 0.18, p = 0.123).  
Covariates associated with rapid bone loss (advanced age, baseline BMD, female sex, low 
baseline weight, postmenopausal status, and interim weight loss) accounted for 10% to 28% of 
trait variation.  No significant evidence of linkage was observed at any skeletal site. 
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Conclusions:  This is one of the first studies to report significant heritability of BMD change for 
weight-bearing and non-weight-bearing bones in an unselected population and the first linkage 
scan for change in BMD.   
3.2 INTRODUCTION 
Osteoporosis is a skeletal condition of major public health significance, contributing toward the 
risk of fragility fracture in women and men of all populations.  The degenerative disorder and 
associated fragility fractures have devastating effects on health, resulting in substantial 
morbidity, and increased mortality for hip and vertebral fractures (1).  Bone mineral density 
(BMD), as the foremost determinant of bone strength and major predictor of future fractures, has 
been extensively studied to help identify the environmental (3,29,117) and genetic factors 
(27,28,30,42) influencing risk for osteoporosis.   
While the contribution of genetics to variation in BMD is widely acknowledged, the 
mechanisms by which genetic factors affect BMD are not well understood.  Bone is dynamically 
maintained through the cycle of bone formation and resorption, with changes in bone mass 
resulting from an imbalance of bone turnover processes.  In general, bone turnover yields a net 
increase in BMD during adolescence and young adulthood leading to peak bone mass attainment, 
followed by a net decrease in BMD resulting in the subsequent loss of bone with advanced age.  
Cross-sectional study designs cannot sufficiently distinguish between processes leading to peak 
BMD acquisition versus loss with age, and this has been a persistent limitation of cross-sectional 
epidemiological and genetic studies of BMD, particularly those carried out in older individuals 
since such studies cannot allow for variation in rates of change in BMD during aging.  
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Longitudinal studies have shown that weight, interim change in weight, alcohol consumption, 
smoking, sex, estrogen replacement therapy, menopausal status, exercise, calcium intake, and 
serum vitamin D level may affect change in BMD over time, and that rates of BMD change may 
differ among skeletal sites (85-88,118).  Rate of bone loss as a risk factor for fracture 
independent of bone mass has recently been reported in a cohort of postmenopausal women 
(mean age of 62 years) (119), reinforcing the clinical importance of change in BMD for bone 
health. 
The degree to which genes affect the rate of BMD change over time remains largely 
unresolved (32).  To date, very few studies have explicitly addressed the role of genetics for 
change in bone traits over time.  One investigation of 25 monozygotic (MZ) and 21 dizygotic 
(DZ) pairs of twins reported no evidence of heritability for decline in radial bone mass over 16 
years (26), while a second study reported greater similarity between 21 MZ than 19 DZ twin 
pairs for annualized percent change in lumbar spine and Ward’s triangle over 1 to 5 years (93).  
A larger study of 177 monozygotic and 185 dizygotic female twin pairs (ages 45 to 82), revealed 
evidence for genetic effects on 5-year change in BMD at the lumbar spine, whole body, and 
forearm, but not hip (95).  Finally, a study of premenopausal sisters from 178 sibships 
demonstrated significant heritability (h2 = 0.29 to 0.35) of 6-year change in femoral neck bone 
mineral content (BMC) and BMD (94).  Although there is some consistency among the results of 
these studies, there are also differences; for example, two studies report significant genetic 
effects on change in hip BMD (93,94), and one does not (95).  These differences may be due to 
the small sample sizes of some studies, length of time elapsed, age range of subjects, and study 
design (twins versus siblings).  Thus, additional research is needed because of the inconsistency 
of results regarding the heritability of BMD change at all high-risk fracture sites (i.e., spine, hip, 
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and forearm) in postmenopausal women.  Furthermore no studies have clearly demonstrated 
heritability of BMD change in men of any age, or performed linkage analysis to find QTLs 
influencing BMD change in any population. 
The San Antonio Family Osteoporosis Study (SAFOS) was designed to investigate the 
influence of genes and environmental factors on BMD and change in BMD over time in Mexican 
Americans.  In the current report, we assessed the cumulative effects of genes (i.e. additive 
heritability) and performed autosome-wide linkage analyses on 5-year longitudinal change in 
BMD (ΔBMD) at several skeletal sites among 300 men and women (>45 years of age) in 32 
extended pedigrees.   
3.3 METHODS 
3.3.1 Subjects and Data Collection 
Recruitment and data collection for the baseline phase of the SAFOS has been previously 
described in detail (30).  The families included for study were selected without regard for health 
outcomes and represent a relatively random sample of low income families from urban San 
Antonio.  In brief, 34 probands of Mexican American descent aged 40 to 60 were identified, and 
all first, second, and third degree relatives of probands and their respective spouses were invited 
to participate in the study.  The only criterion for inclusion of probands was that they have large 
extended families (>6 members) in the San Antonio area.  Anthropometric, medical, and body 
composition data were collected during medical examinations at baseline between 1997 and 
2000.  Body composition data and select covariates were reassessed during a follow-up 
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examination (2002-2006) occurring 3 to 8 years later (mean = 5.5 years).  Lifestyle, medical 
history, and reproductive history data were collected via questionnaire.  Of the original sample of 
895 individuals from 34 families considered in this study (ages 18 to 98), 724 (80.9%) have 
currently been re-enrolled for follow-up.   
The present analyses were confined to the subsample of individuals aged >45 years at 
baseline (n = 370 at baseline, n = 300 at follow-up). This cohort comprises age-eligible members 
of 32 families, among whom are 173 sibling pairs, 126 first-cousin pairs, and 189 other relative 
pairs.  Two of the initial 34 families did not include any relative pairs in this age range and were 
thus excluded from these analyses.  The heritability and linkage analyses carried out in this study 
exclude individuals younger than 45 years at baseline because differences in the biological 
processes that influence bone turnover between younger and older individuals may be due, in 
part, to different genes contributing to bone turnover in younger and older individuals.  This 
speculation is supported by (unpublished) genetic modeling in our sample, showing unequal 
genetic variances between individuals younger and older than 45 years for change in forearm (p 
= 0.04) and hip BMD (p = 0.02).   
Measurements of BMD of the total hip, total lumbar spine (L1-L4), ultradistal radius, 
33% ulna (measured at one-third its total length from the distal end), and whole body were 
obtained by dual-energy x-ray absorptiometry (DXA) at both baseline and follow-up.  Ultradistal 
radius and 33% ulna sites were analyzed separately because these sites are composed of differing 
proportions of cortical and trabecular bone: 33% ulna, like total hip, is largely comprised of 
cortical bone, whereas ultradistal radius, like total spine, is primarily trabecular bone.  During the 
interim between baseline and follow-up clinic visits, DXA equipment was upgraded from a 
pencil beam Hologic 1500W to a fan beam Hologic 4500W absoptiometer (Hologic, Inc., 
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Bedford, MA).  A software upgrade was also included for compatibility of scoring algorithms 
between the two machines.  Cross-calibration of absorptiometry equipment used at baseline and 
follow-up indicated excellent agreement between measurements taken from Hologic 1500W and 
4500W scanners (e.g., R2 > 0.99 for measurements taken at the hip and spine from the two 
scanners on the same 10 subjects) and thus the effect of this equipment change on statistical 
analyses and results should be minimal (see 3.6 Supplemental Material).      
For quality control, the same technician operated all equipment, and phantom 
measurements were taken daily to guard against measurement drift.  Patient positioning was 
performed according to the Hologic positioning protocol; baseline and follow-up scans were all 
compared by the same reviewer, and when necessary, scans were re-analyzed to prevent non-
overlapping regions of interest.    
Covariates considered in this study include sex, age, age2, age × sex, age2 × sex, site-
specific baseline BMD, baseline weight, annualized change in weight, annualized change in 
height, and baseline and follow-up measures of menopausal status (defined by surgical 
menopause or 1 or more elapsed years without menstrual period).  Measurements of all baseline 
covariates were previously described in Mitchell et al. (30); follow-up measurements of 
covariates were assessed identically to the baseline measures.  Annualized change in BMD 
(ΔBMD), height, and weight was calculated as the difference between follow-up and baseline 
measurements divided by the exact elapsed time between clinic visits.  
3.3.2 Genotyping 
Genotyping for SAFOS was carried out as previously described in detail (42) for the San 
Antonio Family Heart Study (SAFHS, the parent project to SAFOS) January 2007 genetic map 
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build:  460 highly polymorphic microsatellite markers across all chromosomes were genotyped, 
and genetic maps were assembled via the program CRI-MAP (120) and confirmed using marker 
locations specified by deCODE (deCODE genetics, Reykjavik, Iceland).  Mean inter-marker 
distance was 7.6 cM, ranging from <0.1 cM to 15.7 cM (Haldane).  
3.3.3 Statistical analyses 
The two goals for analyses presented herein were (i) to determine the extent to which genetic and 
measured environmental factors contribute to the phenotypic variation in ΔBMD at different 
skeletal sites, and (ii) to perform an autosome-wide linkage scan for regions affecting ΔBMD.  
Prior to analyses, the distributions of ΔBMD phenotypes and covariates were assessed, and data 
points greater than 4 standard deviations from trait and covariate means were excluded (0 to 3 
observations removed per trait or covariate).   
As previously described in detail (24,30), heritability of ΔBMD was estimated using 
variance decomposition methods, which model phenotypic variation in ΔBMD at each bone site 
as a function of effects attributable to the measured covariates, additive genetic (based on 
expected allele sharing between pairs of relatives), and unmeasured error components.  This 
model takes the general form , where y∑ +++=
=
n
i
iiijji egXy
1
βμ i is the annualized ΔBMD for 
the ith individual, μ is the sample mean ΔBMD, Xij is the jth covariate for the ith individual, βj is 
the corresponding regression coefficient, gi is the additive genetic effect, and ei is the residual 
error effect.  Pedigree-based maximum likelihood methods were used to estimate these 
parameters, from which residual narrow-sense heritability (h2r, the proportion of total trait 
variance due to the additive genetic component after adjusting for environmental covariates) was 
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determined.  The likelihood ratio test was used to assess the significance of model parameters by 
comparing the full model (all covariates and additive genetic effects) with a nested model 
lacking a specific component.  The test statistic asymptotically follows the chi-squared 
distribution with one degree of freedom for testing covariates, and follows a 50:50 mixture of 
chi-squared distribution with one degree of freedom and a point mass at zero for testing 
heritability.  Power was 94%, 84%, and 66% to detect true heritability of 0.45, 0.35, and 0.25, 
respectively at α = 0.05.  The analysis of each ΔBMD phenotype was limited to individuals with 
observed data for all retained covariates.  The proportion of total variance attributable to 
covariates was estimated by comparing the estimated variance in the model excluding all 
significant covariates to that of the model including significant covariates.   
Multipoint linkage scans were performed using the variance components method, which 
extends the above model by also including the effect of a presumed QTL, , as a component of 
ΔBMD genetic variance.  Maximum likelihood methods were used to estimate  based on the 
expected covariance of relatives due to their identity-by-descent (IBD) at a given marker (two-
point analyses) or at an arbitrary chromosomal location (multipoint analyses) in tight linkage 
with the presumed QTL.  A Markov Chain Monte Carlo algorithm, as implemented in Loki, was 
used to calculate multipoint IBD probabilities using data from all genotyped individuals (102).  
The likelihood ratio test was used to compare the linkage model to the polygenic (i.e. no linkage, 
 = 0) model, and findings were reported in LOD scores (i.e. log
2
mσ
2
mσ
2
mσ 10 of the likelihood ratio).  To 
remedy the potential consequence of phenotype distribution on calculated LOD scores, 10,000 
simulations of an unlinked marker were performed and linkage analyses carried out on each to 
determine the empirical LOD score distribution for each phenotype.  Linear LOD score 
adjustments according to the empirical distribution were then applied to our findings (104).   
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Power to detect linkage was low:  20% and 33%, respectively, to detect a QTL describing 35% 
of phenotype variance at a LOD threshold of 2.0 and 1.5.  Genetic analyses were performed 
using the Sequential Oligogenetic Linkage Analysis Routines (SOLAR) software (101).  For 
illustrative purposes, histograms and LOD score plots were created in R (R Foundation for 
Statistical Computing, Vienna, Austria).   
3.4 RESULTS 
Population characteristics of the 300 individuals in our study are summarized in Table 3.1.  
Mean length of follow-up was 5.5 years and ranged from 3.2 to 8.0 years.  The prevalence of 
obesity in the sample was high, as indicated by mean body mass index (BMI) for men and 
women of 31.1 and 32.9 kg/m2, respectively.  Distributions of annualized ΔBMD for different 
skeletal sites, calculated from measurements taken at baseline and follow-up, are depicted in 
Figure 3.1.  Negative values indicate average yearly decline in BMD per year, whereas positive 
values indicate average yearly gain.  BMD declined, on average, for lumbar spine, ultradistal 
radius, and whole body, but not 33% ulna or total hip.  The differences in magnitude and 
direction of ΔBMD across skeletal sites reflects the site-specific consequence of aging on bone; 
indeed, correlations for ΔBMD among skeletal sites are low (r = 0.15 to 0.41).  Also, mean 
ΔBMD of the spine differed markedly between men and women (p < 0.001), possibly due to the 
high prevalence of osteoarthritis and aortic calcification in men, leading to inflated densitometry 
values with increasing age (113-115).    
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Table 3.1.  Mean population characteristics (SD) [95% CI] 
 
  total sample women   men   
trait n = 300   n = 197   n = 103   
length of follow-up (years) 5.5 (0.6) 5.5 (0.6) 5.4 (0.6) 
demographic       
age (years) 56.7 (8.8) 56.3 (8.7) 57.6 (9.0) 
lifestyle       
alcohol consumption (%) 27.0 - 15.7 - 48.5 - 
smoking history (%) 17.3 - 9.6 - 32.0 - 
medical       
diabetes (%) 28.3 - 28.4 - 28.2 - 
reproductive       
oral contraceptives (%) 0.7 - 1.0 -  - 
post-menopausal (%) 41.2 - 62.8 -   
anthropometric       
height (cm) 160.0 (8.9) 155.2 (5.4) 169.1 (6.9) 
weight (kg) 82.7 (18.8) 79.3 (17.4) 89.3 (19.7) 
BMI (kg/m2) 32.3 (6.6) 32.9 (6.9) 31.1 (6.0) 
change in height (cm/year) -0.12 (0.30) -0.14 (0.28) -0.07 (0.32) 
change in weight (kg/year) 0.00 (1.37) 0.09 (1.19) -0.19 (1.66) 
change in BMI (kg/m2/year) 0.05 (0.53) 0.10 (0.50) -0.04 (0.58) 
BMD (g/cm2)       
total hip 0.96 (0.16) 0.93 (0.15) 1.02 (0.15) 
total spine 1.01 (0.17) 0.97 (0.16) 1.07 (0.17) 
ultradistal radius 0.47 (0.08) 0.44 (0.07) 0.52 (0.07) 
33% ulna 0.67 (0.11) 0.62 (0.07) 0.77 (0.08) 
whole body 1.10 (0.13) 1.05 (0.12) 1.19 (0.10) 
annual BMD change (mg/cm2/year)       
total hip 0.3 [-.09, 1.5] -0.2 [-1.8, 1.3] 1.2 [-0.6, 3.1] 
total spine -4.6 [-6.0, -3.2] -6.9 [-8.6, -5.2] -0.2 [-2.3, 1.9] 
ultradistal radius -5.8 [-6.5, -5.2] -5.2 [-6.0, -4.8] -7.0 [-8.1, -5.9] 
33% ulna 7.0 [6.2, 7.8] 6.3 [5.5, 7.2] 8.3 [7.0, 9.6] 
whole body -5.6 [-6.5, -4.6] -4.3 [-5.6, -3.1] -7.9 [-9.3, -6.6] 
 
 51 
 Figure 3.1.  Distributions of annual change in BMD (mg/cm2/year) for (i) total hip, (ii) total lumbar spine, (iii) 
ultradistal radius, (iv) 33% ulna, and (v) whole body.  Gray bars represent total sample (n = 300); black bars 
represent the subset of women (n = 197). 
 
 
Table 3.2 shows for each bone site the residual heritability of ΔBMD after adjusting for 
sex, age, age2, age × sex, age2 × sex, baseline BMD, baseline weight, menopausal status, interim 
change in weight, and (for spine and whole body ΔBMD only) interim change in height.  In light 
of the well-documented bone loss following menopause, we adjusted ΔBMD for baseline post-
menopausal status to correct for women having already undergone transient menopause-related 
bone loss, as well as interim incidence of menopause to correct for women undergoing rapid 
menopause-related bone loss during the years of follow-up.  After incorporating covariates, we 
observed significant residual heritability for ΔBMD of the total hip, total spine, and 33% ulna 
(h2r = 0.31 to 0.44; p < 0.03 for all).  Additionally, we observed modest residual heritability for 
ultradistal radius ΔBMD (h2r = 0.25, p = 0.06), but not whole body ΔBMD (h2r = 0.18, p = 0.12).  
Approximately 10% to 30% of total variation in ΔBMD was attributable to covariates.  
Heritability of unadjusted ΔBMD (not shown in table) was similar to heritability after covariate 
adjustment for all bone sites. 
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Table 3.2.  Residual heritability of BMD change. 
 
BMD site n h2r SE p-value R2
total hip 272 0.44 0.24 0.017 0.19 
total spine 272 0.42 0.18 0.005 0.28 
ultradistal radius 277 0.25 0.18 0.064 0.10 
33% ulna 277 0.31 0.17 0.021 0.11 
whole body 253 0.18 0.17 0.123 0.16 
 
h2r = residual heritability   
R2 = proportion of variation attributable to covariates:  sex, age, age2, age × sex, 
age2 × sex, baseline BMD, baseline weight, baseline post-menopausal status, 
interim menopause, interim change in weight, interim change in height (included 
only for spine and whole body ΔBMD) 
 
 
Whole genome multipoint linkage scans were performed for ΔBMD at each skeletal site 
(Figure 3.2).  No evidence of linkage was detected at genome-wide significance; the greatest 
linkage signal was observed for 33% ulna ΔBMD with a LOD score of 1.90 at 81 cM on 
chromosome 3p (unadjusted p = 0.0018).  This region has previously been implicated in lumbar 
spine BMD in unselected twins and extremely discordant or concordant sib pairs (54), and for 
general BMD (i.e. not skeletal site-specific) in a meta-analysis of 11 whole-genome BMD scans 
(59).  A novel signal for hip ΔBMD with a LOD score of 1.75 at 103 cM on chromosome 6q was 
also observed (unadjusted p = 0.0008).  
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 Figure 3.2.  Multipoint LOD scores for change in BMD (mg/cm2/year) across chromosomes 1 to 22. 
3.5 DISCUSSION 
Numerous family and sibling studies of peak BMD have been performed in a variety of 
populations, and these studies have universally shown the high heritability of peak BMD 
(17,24,25,29,30). Many whole genome linkage scans have also been performed, with QTLs 
reported at a number of chromosomal regions, though specific QTLs have rarely been replicated 
across studies (27,28,42,48,50,51,54,58,121,122), probably due, in part, to genetic heterogeneity 
among the populations studied.  Analyses of BMD data from these previous studies, however, 
cannot adequately distinguish between loci affecting loss of BMD with age and those affecting 
the acquisition of peak bone mass occurring in young adulthood.  Moreover, the models of BMD 
variation in these cross-sectional family studies generally assume universal rates of change with 
age (i.e. by adjusting BMD for age and/or age2) thereby further reducing their ability to find 
genes that influence individual rates of change.  In the current study, we have directly calculated 
ΔBMD from longitudinal measurements, to better investigate the role of genes on ΔBMD. 
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Our study provides support that the rate of bone loss in middle-to-older-aged Mexican 
Americans is heritable.  Specifically, we estimated that genes account for 25% to 44% of 
residual variation in ΔBMD for three bone sites (hip, spine, and forearm) at high risk of fracture.  
The confidence intervals surrounding these estimates, however, are wide – a feature that is partly 
a consequence of our sample size (n = 300) of adults >45 years of age from large 
multigenerational families, and partly due to the measurement uncertainty for ΔBMD.  We have 
reported heritability estimates for the combined cohort of men and women aged >45 years; 
heritability estimates for ΔBMD of similar magnitude were obtained when we restricted analysis 
to women only (n = 197), with the exception that heritability of ΔBMD at the ulna was reduced 
and did not differ significantly from zero (results not shown).  Sample size limitations precluded 
performing genetic modeling of ΔBMD in men alone.  In general, heritability estimates of 
ΔBMD in our sample (both overall, and in the women-only subset) are similar in magnitude to 
recently published estimates obtained in both premenopausal (94) and peri- and post-menopausal 
women (95), with the exception that, unlike in our study, significant genetic effects on bone loss 
of the hip were not observed for the latter (95).     
Though significantly heritable, our genome-wide linkage scan for ΔBMD revealed no 
strong evidence for QTLs (including in the women-only subset; results not shown).  However, 
power in our sample was very low to detect QTLs having relatively modest effects (e.g. at a 
LOD threshold of 2.0 we have 20% power to detect a locus accounting for 35% of residual 
phenotypic variance), and it is likely that QTLs of modest effect sizes were missed.   
While the cumulative influence of genes on ΔBMD is large, the contribution of 
environmental factors is also important; measured covariates accounted for 10% to 28% of 
phenotypic variation.  Associations with BMD of several of the environmental correlates 
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identified in this study, including age, female sex, postmenopausal status, low body weight, and 
weight loss, have been detected in previous studies (85,86,118,123).  Interestingly, we observed 
differences in magnitude and direction for ΔBMD across skeletal sites, as has been observed by 
others, although not always for the same sites [9-11].  Unfortunately, there are insufficient 
reports of ΔBMD across multiple age ranges and ethnic groups to develop hypotheses regarding 
potential mechanisms for these differences at this time.  However, this result, combined with the 
observed differences in heritability and variation attributable to environmental correlates among 
bone sites, suggests that factors regulating 5-year ΔBMD may vary across the skeleton. 
A major strength of this study is the use of extended families and longitudinal 
measurements of BMD to investigate the genetics of bone loss.  Previous linkage scans for 
BMD, of which there have been many, have been ill-suited to find genes affecting change, and 
all previous attempts to estimate the heritability of ΔBMD have been carried out exclusively in 
twins or siblings (26,93-95).  By using information from many types of relative pairs (cousins, 
avuncular pairs, etc.) in addition to siblings, our estimates of heritability more accurately reflect 
the truly genetic factors affecting ΔBMD by reducing the contribution of familial non-genetic 
factors such as household effects to our heritability estimation.  Other strengths of this study are 
the inclusion of both axial (weight-bearing) and peripheral (non-weight-bearing) skeletal sites, 
and the incorporation into our models of important covariates previously shown to have potential 
effects on ΔBMD.  Furthermore, this is one of the first studies to consider ΔBMD in a population 
of Mexican descent and, to our knowledge is the only study, to date, reporting a linkage scan for 
a change in bone phenotype.   
Despite these strengths, several limitations of this study must be acknowledged.  
Foremost is the fact that different absorptiometers were used to collect baseline and follow-up 
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BMD measurements.  However, the BMD scoring algorithms were standardized to the degree 
possible and our cross-calibration experiment (albeit in a limited number of subjects) confirmed 
outstanding agreement in measurements between the two scanners (see 3.3 Methods and 3.6 
Supplemental Material).  Other limitations and sources of error for this study include the reduced 
sample size available for follow-up (86.5%) and the possibility of non-random loss to follow-up 
with respect to bone health.  Also, power to detect significant linkage was limited, and our 
sample size and methods preclude direct detection of gene × environment interactions (in 
particular, gene × sex and gene × menopausal status interactions).  Analyses could not be 
performed separately in pre- and postmenopausal women (again, due to sample size); however, 
the similarity of our results with those in both pre- and postmenopausal women in other studies 
(94,95) suggests that the impact of this limitation may be not be critical.  Finally, there are 
inherent drawbacks to using DXA to assess BMD, notably the estimation of bone mineral 
content from a two-dimensional projection, which fails to precisely account for the size (depth) 
of bone (124).  These limitations, however, would reduce our chances of detecting heritable 
effects or QTLs, but would not inflate them. 
In conclusion, this study provides evidence that ΔBMD is heritable for several skeletal 
sites in middle-aged men and women.  Our results corroborate recent findings for significant 
heritability of change in femoral neck BMD in premenopausal women (94), as well as other 
previous twin studies (26,93) and racial comparisons (8,14).  Moreover, we report on the 
genetics of bone loss in Mexican Americans, a population that is under-represented in the 
osteoporosis literature.  While evidence for the heritability of age-related ΔBMD is mounting, 
the localization of QTLs, and identification of specific genetic factors contributing to variation in 
 57 
bone loss has yet to be realized.  Such genes represent a novel area for investigation into the risk 
factors for osteoporosis. 
3.6 SUPPLEMENTAL MATERIAL  
3.6.1 DXA measurement and cross-validation 
Due to an upgrade in equipment, densitometry was carried out on a pencil-beam Hologic Model 
1500 at baseline examination (1997-2000) and a fan-beam Model 4500W at follow-up 
examination (2002-2006).  For both densitometers, areal BMD was calculated by manufacturer’s 
software as per current recommendations by dividing bone mineral content (g) by the projected 
area of the region scanned (cm2).  Precision of pencil-beam DXA was 0.009 g/cm2 for spine, 
0.007 g/cm2 for total hip, and 0.002 g/cm2 for the manufacturer’s spine phantom.  Precision of 
fan-beam DXA was 0.006 g/cm2 for spine, 0.007 g/cm2 for hip, and 0.002 g/cm2 for radius.   
Based on the precision of our equipment, least significant change (at 95% confidence) was 3.2 
mg/cm2/year for hip, 3.1 mg/cm2/year for spine, and 1.1 mg/cm2/year for forearm DXA 
measurements.   
To address the comparability in our study of measurements taken from Hologic 1500 and 
4500W scanners, we performed cross-calibration of absorptiometry equipment used at baseline 
and follow-up on 10 participants.  Measurements obtained from the two scanners showed near-
perfect agreement (R2 values = 99.95%, 99.81%, and 99.87% for spine, total hip, and femoral 
neck sites, respectively; p < 10-13 for all).  Moreover, regression slopes (0.99, 0.99, and 1.01, 
respectively, for spine, total hip, and femoral neck; p < 10-13 for all) and paired T-tests (p > 0.1, 
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for all) revealed no evidence of systematic or mean differences between absorptiometers.  This 
evaluation of equipment indicates that measurements from Hologic 1500 and 4500W scanners 
used in this study are comparable, and that 5-year change in BMD can be adequately calculated.  
Cross-calibration was not performed for forearm BMD, although we expect that measurements at 
this site are equally comparable.   
3.6.2 Robustness of methods to measurement error  
Though we found no evidence to suggest that systematic differences exist in the measurements 
between scanners, we have nonetheless employed statistical methods that are robust to potential 
differences.  If present, such bias (e.g. systematic measurement error) would decrease our power 
to detect covariate effects and attenuate our estimate of heritability and linkage, but should not 
otherwise affect our results.  That is, machine differences leading to biased estimates of BMD 
change could prevent us from assessing environmental and genetic factors affecting BMD 
change, but would not produce false positive results or lead to overestimation of effects sizes.  
Our findings, therefore, are conservative.  Furthermore, we recognize that deviations from 
absolute agreement between machines would not adversely affect the genetic analyses as long as 
the relative BMD between individuals as measured by each scanner is accurate (i.e. variances are 
comparable).  In other words, as long as BMD measured for an individual at baseline is accurate 
relative to the baseline measurements of the rest of the study sample, and the same holds for 
measurements at follow-up, the estimation of heritability will be unaffected by inter-machine 
differences.  This is because the genetic modeling used to assess heritability decomposes the trait 
variance into genetic and environmental components irrespective of the trait mean.   
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To demonstrate this point, we removed the possibility of any inter-machine effects by 
first standardizing (mean = 0, SD = 1) the BMD measurements in our sample separately at 
baseline and follow-up, and then analyzing yearly change in standardized values.  This process 
retains the information of individuals' measurements relative to the sample, but not of the 
absolute magnitude of measurements.  In doing so, potential unknown machine differences that 
could invalidate direct inter-machine comparisons are avoided.  Results (not shown) of change in 
standardized BMD are very similar to the absolute change reported herein.  Likewise, results (not 
shown) of percent change in BMD were also similar. 
3.6.3 Attenuation of heritability due to measurement error 
The precision of DXA, which is excellent when looking at cross-sectional BMD measurements, 
is poor when looking at change over time, leading to considerable uncertainty of actual rates of 
change.  Therefore, rates of change assessed in this study are notably crude, with a large 
percentage of observations being less than our measurement uncertainty (i.e. no measurable 
change).  Since noise constitutes a substantial portion of the variation in observed rates of 
change, our results represent a considerable underestimation of the heritability of observed BMD 
change compared to that of true change (free of such measurement error) (94).  Noise due to our 
crude assessment of BMD change effectively drowns the heritability signal, and diminishes our 
ability to detect linkage.    
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3.6.4 Parallel analysis of the subset aged 45 to 65 years 
As previously discussed, the question of choosing the appropriate range of ages to analyze (to 
reduce genetic heterogeneity) is imperative to the success of this study.  We presented results, 
above, for the cohort of men and women >45 years of age.  However, analysis of a narrower age 
range (possibly limited to a more homogenous phase of bone metabolism with regard to 
genetics) may improve our ability to detect the genetic contribution to ΔBMD.  To this end, we 
have repeated analyses while restricting our sample to individuals 45 to 65 years at baseline (n = 
243).  This cohort comprises members of 32 families, among which are 138 sibling pairs, 112 
first-cousin pairs, and 86 other relative pairs.  Individuals older than 65 years at baseline were 
excluded primarily based on observed differences in the epidemiology of ΔBMD between 
individuals 45 to 65 and >65 years.  Unlike in individuals 45 to 65 years of age, ΔBMD declined 
rapidly with age in those older than 65 years (Figure 3.3), which suggests that individuals >65 
years may have entered a different phase of bone metabolism, possibly influenced by different 
genes.   
The cumulative effect of genetic factors on ΔBMD in those aged 45 to 65 years was 
assessed while simultaneously modeling the effects of the following covariates:  sex, baseline 
BMD, baseline weight, baseline post-menopausal status, interim menopause, interim change in 
weight, and (for spine and whole body only) interim change in height.  Heritability estimates of 
ΔBMD for total hip, lumbar spine, midpoint and ultradistal radius, and whole body are shown in 
Table 3.3.   
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 Figure 3.3.  Change in total hip BMD by age.  Local regression curves shown for participants 45 to 65 years of age 
(dotted line) and >65 years of age (solid line).  Rates of change are significantly associated with age in participants 
>65 years of age (p = 0.025), but not in participants 45 to 65 years of age.  
 
Figure 3.4 depicts the results of genome-wide linkage scans for ΔBMD at each skeletal 
site.  A suggestive QTL (maximum LOD = 2.5 at 103 cM) for hip ΔBMD was observed on 
chromosome 6q between DNA markers D6S1270 and D6S1021.  Figure 3.5 shows the adjusted 
multipoint LOD scores across chromosome 6 for hip ΔBMD.  This possible QTL signal was not 
observed in our previous cross-sectional linkage scan of baseline hip BMD (42), suggesting that 
this chromosomal region may affect ΔBMD but not peak BMD.  No other significant or 
suggestive linkage signals were identified for hip, midpoint radius, ultradistal radius, spine or 
whole body ΔBMD. 
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 Table 3.3.  Residual heritability of change in BMD (45 to 65 years) 
BMD site n h2r SE p-value R2
total hip 222 0.53 0.24 0.006 0.16 
total spine 224 0.43 0.21 0.008 0.22 
midpoind radius 227 0.44 0.23 0.020 0.08 
ultradistal radius 228 0.33 0.23 0.055 0.07 
whole body 210 0.24 0.17 0.055 0.10 
 
 
Compared to the sample of all participants >45 years of age, results in the subset aged 45 
to 65 were somewhat different.  Point estimates for the residual heritability of ΔBMD at the hip 
(h2r = 0.53 vs. 0.44), ultradistal radius (h2r = 0.33 vs. 0.25), and whole body (h2r = 0.24 vs. 0.18) 
were greater in subset 45 to 65 years.  Likewise, the linkage signal for hip ΔBMD on 
chromosome 6 was greater in the subset 45 to 65 years (maximum LOD = 2.5 vs. 1.7).  The 
significance of the observed difference in heritability and linkage results between samples with 
and without inclusion of individuals >65 years was tested using a type of sensitivity analysis as 
described by Atwood et al. (125). 
 
 
Figure 3.4.  Multipoint LOD scores for change in BMD across chromosomes 1 to 22 (45 to 65 years). 
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Figure 3.5.  Chromosome 6 multipoint LOD score plot for change in hip BMD 
 
In brief, to determine if these differences in heritability estimates and LOD scores are due 
only to the change in sample size, or alternatively, due to something intrinsic to the set of 
individuals >65 years, we re-ran our analyses for 1000 subsets in which 57 individuals (i.e. the 
difference in sample size) were removed at random from the total sample >45 years.  This 
provides a sense of the null distribution for differences in heritability and maximum LOD scores 
due to changes in sample size alone.  Based on these random subsets, for example, we found that 
point estimates of heritability for hip ΔBMD ranged from 0.0 to 0.75, and concluded that the 
difference in magnitude of heritability estimates observed with and without including 
participants >65 years was not significantly greater than expected due to the change in sample 
size (p = 0.13).  In other words, inclusion or exclusion of participants >65 years does not affect 
heritability estimates.  On the other hand, based on QTL scans of the 1000 random subsets, we 
found that, indeed, the inclusion of individuals >65 years reduced the observed linkage signal 
more than expected based solely on change in sample size (p = 0.02); that is, the observed QTL 
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result was in the upper 2% of the empirical distribution.  This result suggests that heterogeneity 
may have been introduced by inclusion of the subset of individuals >65 years, specifically, which 
in turn diminished the evidence of linkage.  Therefore, restricting our analyses to those aged 45 
to 65 years may be an appropriate approach for dissecting the genetic factors influencing ΔBMD, 
although a large sample size would be required to achieve adequate power.   
In the subset aged 45 to 65 years, the putative linkage signal on chromosome 6q, which 
exceeds the Lander and Kruglyak recommended threshold for "suggestive linkage" (99), is 
particularly exciting because it was not identified in our previously reported genome-wide 
linkage scan of cross-sectional BMD from this population (42), and has not been implicated as a 
QTL for peak BMD in other studies.  Thus, this putative QTL may influence bone loss, and not 
peak bone mass, and may serve as a principal candidate region for higher-resolution analyses.  
At least three biologically plausible candidate genes fall within our linkage peak on 
chromosome 6, among which is WNT1-inducible signaling pathway protein 3 (WISP3; located 
at chromosomal position 113 cM), a downstream member of the WNT pathway needed for 
proper skeletal growth.  Several mutations in WISP3 are associated with progressive 
pseudorheumatoid arthropathy of childhood, an autosomal recessive skeletal disorder that results 
in destructive bone alterations and cartilage loss (126).  A second gene in this region necessary 
for normal skeletal development is collagen type X alpha-1 (COL10A1; 116 cM).  Specific 
mutations in COL10A1 cause Schmid-type metaphyseal chondrodysplasia (127), a form of short-
limbed dwarfism with associated skeletal dysmorphisms.  Because of its role in femoral neck 
development, possibly determining length, width, and neck-shaft angle (128), COL10A1 may 
also be involved in variation in hip ΔBMD with age.  A third noteworthy gene in this region is 
osteopetrosis associated transmembrane protein 1 (OSTM1; 108 cM), an important regulator of 
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bone resorption (129).  Possibly, one of these three candidate genes contributes to our linkage 
peak, although it should also be noted that there are currently 248 genes that map to this 
chromosomal region (i.e. between 85 cM to 120 cM on chromosome 6) that could also contribute 
to our linkage signal.  To our knowledge, no QTLs for bone mineral density have been identified 
in homologous chromosomal regions in mouse (Mouse Genome Informatics 3.54; updated 
06/23/2007) (130) or rat (Rat Genome Database; updated 06/11/2007) (131).  Future exploration 
for genetic factors in this chromosomal region is needed, and may lead to new insights into the 
causes of common variation in rates of bone loss and management of bone health.   
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4.1 ABSTRACT 
We assessed heritability and performed genome-wide linkage analysis for early bone loss in a 
population-based sample of 327 Mexican American men and women from large pedigrees.  Bone 
loss was heritable for the hip and forearm, with evidence of linkage to chromosomes 1q, 6q and 
11p.      
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Introduction:  Bone loss occurs as early as the third decade and its cumulative effect throughout 
adulthood may impact risk for osteoporosis in later life, however the genes and environmental 
factors influencing early bone loss are largely unknown.  We investigated the role of genes on 
the rate of change in bone mineral density (BMD) in participants of the San Antonio Family 
Osteoporosis Study. 
 
Materials and Methods:  Rate of BMD change in 327 Mexican Americans (ages 25-45 years) 
from 32 extended pedigrees was calculated from DXA measurements at baseline and follow-up 
(5.6 years later).  Family-based likelihood methods were used to estimate heritability and 
perform genome-wide linkage analysis (using a 7.6 cM map) for BMD change of the proximal 
femur, lumbar spine, and forearm.   
 
Results:  Rate of BMD change was significantly heritable for total hip, ultradistal radius and 
33% ulna (h2r = 0.34, 0.34, 0.35, respectively, p < 0.01 for all), modestly heritable for femoral 
neck (h2r = 0.22, p = 0.06) and not heritable for spine BMD (p = 0.5).  Covariates associated with 
BMD change included age, sex, baseline BMD, menopause, BMI, and interim BMI change, and 
accounted for 5% to 24% of phenotype variation.  A significant QTL (LOD = 3.6) for femoral 
neck BMD change was observed on chromosome 1q23; suggestive signals were also observed 
for ulna BMD change on chromosome 11p14-15 (LOD = 2.5) and radius BMD change on 
chromosome 6q (LOD = 2.9). 
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Conclusions:  We observed that early BMD loss was heritable, and performed one of the first 
linkage studies for BMD change.  Linkage to chromosome 1q23 suggests this region may harbor 
one or more genes involved in regulating early bone loss of the femoral neck.   
4.2 INTRODUCTION 
Peak bone mass and rates of bone loss following menopause in women and later in life in men 
are commonly acknowledged to be important risk factors for osteoporosis.   In fact, Hui et al., 
suggest that the contributions of peak bone mass acquisition and bone loss after menopause are 
roughly equal in determining bone mass in women 70 years of age (132).  Over the past three 
decades, many of the factors that influence peak bone mass in adults, as well as bone loss among 
older men and women have been identified (3,6,85-89).  In addition to environmental factors, 
numerous studies have documented that peak bone mineral density (BMD) is highly heritable 
(17,24-26,30,133) and many quantitative trait loci (QTLs, i.e. implicated chromosomal regions 
potentially harboring regulatory genes) have been reported (34,36-38,41-46,48-
51,54,55,58,59,134,135).  More recently, studies have clearly demonstrated that genetic factors 
regulate BMD change at several skeletal sites in women and older men.  Specifically, the 
heritability of the femoral neck in premenopausal women (94), lumbar spine, forearm, and whole 
body (but not hip) in peri- and postmenopausal women  (95), and lumbar spine, hip, and forearm 
(but not whole body) in older men and women (>45 years) (116) has been demonstrated.  Studies 
to identify specific genes influencing peak bone mass and bone loss in older individuals are 
ongoing. 
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Although many studies have investigated genetic and environmental factors influencing 
peak bone mass and bone loss among older individuals, few studies have looked at the factors 
affecting early change in BMD among young adults, particularly the role of genetics on bone 
loss (26,93).  While most cross-sectional studies report minimal bone loss among individuals 
<50 years of age (136), more recent longitudinal studies have revealed significant rates of bone 
loss occurring as early as the third decade in women (92,94,137-139) and men (92,140).  
Furthermore, results from cross-sectional and longitudinal studies indicate that the onset of 
trabecular bone loss may begin in early adulthood, whereas the onset of cortical bone loss is 
delayed until mid-life in women and later in life in men (17,92).  Thus, bone health later in life 
may depend upon early bone loss, in addition to peak bone mass and advanced age-related bone 
loss.  Furthermore, the importance of early bone loss with regard to later bone health may depend 
on the trabecular and cortical content of a particular skeletal site.  
One study has reported that bone loss of the femoral neck is heritable in premenopausal 
Caucasian women (94), but to date, no study has assessed the genetic contribution to early bone 
loss at other skeletal sites or in men (younger than 45 years of age).  Furthermore, no specific 
QTLs for longitudinal BMD change have been identified in any population.   
As part of the San Antonio Family Osteoporosis Study, we sought to investigate the role 
of genetic factors on bone loss in younger individuals at a number of skeletal sites.  Specifically, 
we have estimated the heritability of 5-year change in BMD in 327 Mexican American men and 
women (ages 25 to 45) from large multigenerational kinships, and performed genome-wide 
linkage analysis in search of QTLs influencing common variation in early bone loss.   
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4.3 MATERIALS AND METHODS 
4.3.1 Recruitment and data collection 
Data collection for baseline and follow-up phases of the San Antonio Family Osteoporosis Study 
have been fully described previously (30,116).  In brief, participants from 34 multigenerational 
families were collected from a low-income neighborhood via a house-to-house recruitment 
protocol.  Probands meeting eligibility criteria (i.e. aged 40 to 60 years and having large families 
in the San Antonio area) and all first, second, and third degree relatives and spouses were invited 
to participate irrespective of current health outcomes.  Participating families represent a 
fundamentally unselected, population-based sample of Mexican American kinships, for which 
longitudinal data are available on 724 individuals.    
Anthropometric, medical, and body composition data were collected during medical 
examinations at baseline (from 1997 to 2000) and follow-up (5.6 years later; from 2003 to 2006).  
Lifestyle, medical history, and reproductive history data were concomitantly assessed at both 
times via questionnaire.  Approximately 81% of the original study participants were re-enrolled 
for follow-up. 
The aim of the present study was to assess environmental and genetic influences on early 
bone loss; therefore analysis was performed in the subset of participants aged 25 to 45 years at 
baseline (n = 327).  This cohort comprised participants from 32 kinships, including 1434 relative 
pairs (206 siblings, 96 avuncular relationships, 484 first cousins, and 648 other relationships).   
 BMD measurements of femoral neck, total hip, total lumbar spine (L1-L4), ultradistal 
radius, and 33% ulna (measured at 33% of total length from the distal end) were obtained by 
dual-energy x-ray absorptiometry (DXA) at both baseline and follow-up.  Different sites of 
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radius and ulna are included because they represent different proportions of trabecular and 
cortical bone: ultradistal radius is largely trabecular, whereas 33% ulna is mostly cortical bone.  
During the interim between baseline and follow-up clinic visits, DXA equipment was upgraded 
from the Hologic 1500W model to the 4500W model (Hologic Inc., Bedford, MA), along with a 
software update to ensure comparability of scoring algorithms.  Cross-calibration of 
absorptiometers showed near-perfect agreement on 10 test subjects (R2 = 99.9%, 99.8%, and 
99.9% for spine, total hip, and femoral neck sites, respectively; p < 10-13 for all).  No mean 
difference between absorptiometers was detected (paired t-test p > 0.1 for all sites).  Precision of 
Hologic 1500W was 0.009 g/cm2 for spine, 0.007 g/cm2 for total hip, and 0.002 g/cm2 for the 
manufacturer’s spine phantom.  Precision of Hologic 4500W was 0.006 g/cm2 for spine, 0.007 
g/cm2 for hip, and 0.002 g/cm2 for radius.  For quality control, all DXA readings were performed 
by the same trained technician, measurement drift was prevented by calibrating equipment daily 
on the phantom, and baseline and follow-up scans were evaluated by the same reviewer ensuring 
comparability of regions of interest. 
To prevent any unknown inter-machine differences from affecting our assessment of 
rates of BMD change, measurements of BMD were standardized (mean = 0, SD = 1) 
independently at baseline and follow-up.  Annual change in standardized BMD was calculated as 
the difference divided by exact elapsed time between standardized baseline and follow-up 
measurements.  This process retains the information of individual measurements relative to the 
sample, but not of the absolute magnitude of measurements, thus avoids potential unknown 
machine differences that could invalidate direct inter-machine comparisons.  Rates of BMD 
change are expressed as percent of a standard deviation per year (%SD/year).  Based on the 
precision of our DXA equipment, the least significant change (LSC; detectable with 95% 
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confidence) was ± 2.22 %SD/year for hip, ± 2.54 %SD/year for spine, and ± 1.53 %SD/ year for 
forearm.  Observed rates of change less than the LSC values were not significantly different than 
zero (i.e. no observed change).  Of the 327 participants included in this study, 65%, 73%, and 
81% experienced significant rates of change in BMD (i.e. greater than the LSC) at the hip, spine, 
and forearm, respectively. 
Covariates included in our analysis were sex, baseline age (years), site-specific baseline 
BMD (g/cm2), baseline body mass index (BMI; kg/m2), yearly interim change in BMI 
(kg/m2/year; calculated as difference between baseline and follow-up measurements divided by 
the exact elapsed time), and interim entrance into menopause (yes or no; defined as surgical 
menopause or 1 or more years since most recent menstrual cycle).  Covariate measurements were 
collected identically at baseline and follow-up clinic visits, as previously described (30).  
4.3.2 Genotypes 
Automated genotyping of the San Antonio Family Osteoporosis Study participants has 
previously been described (42).  DNA from lymphocytes was amplified via polymerase chain 
reaction using fluorescently-tagged primers (MapPairs Human Screening Set Versions 6 and 8; 
Research Genetics, Huntsville, AL, USA) to detect repeat alleles at highly polymorphic 
microsatellite markers.  Aliquots of amplified DNA were genotyped with Applied Biosystems 
Model 377 DNA Sequencers and analyzed with GeneScan and Genotyper DNA Fragment 
Analysis software (Perkin Elmer, Foster City, CA, USA).  CRI-MAP (120) was used to assemble 
460 microsatellite markers across chromosomes 1 to 22 into a genetic map, for which all marker 
positions were confirmed by deCODE (deCODE genetics, Reykjavik, Iceland).  Mean inter-
marker distance was 7.6 cM. 
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4.3.3 Statistical analyses 
Distributions of BMD (at baseline and follow-up) and covariates were assessed, and outliers 
greater than 4 SD from trait means were excluded (0 to 3 observations removed per trait).  
Heritability of rate of BMD change was estimated in a variance components framework, which 
models phenotypic variance as a function of effects due to measured covariates, additive 
polygenic (based on average allele-sharing between relative pairs), and error components.  The 
general form of this model is , where y∑ +++=
=
n
i
iiijji egXβμy
1
i is the rate of BMD change for 
the ith individual, μ is the sample mean rate of BMD change, Xij is the jth covariate for the ith 
individual, βj is the corresponding regression coefficient, gi is the additive polygenic effect, and 
ei is the residual error effect.  Model parameters were estimated using pedigree-based maximum 
likelihood methods, from which residual heritability (h2r, i.e. the proportion of phenotype 
variance attributable to the additive genetic component after removing variation due to 
covariates) was estimated.  The significance of covariate and heritable components were tested 
via the likelihood ratio test, which compares the likelihood of models including and excluding 
each component.  This test follows a chi-squared distribution with 1 degree of freedom for 
testing covariates, and a 50:50 mixture of a point mass at zero and a chi-squared distribution with 
1 degree of freedom for testing heritability.  Only covariates with significant effects at α = 0.1 
were retained in final models for each skeletal site.  The proportion of variance explained by 
covariates was determined by comparing models including and excluding retained covariates.  
Models of rates of BMD change for each skeletal site were restricted to participants with data on 
all retained covariates.  Power to detect true heritability of 0.25, 0.35, and 0.45 was 70%, 85%, 
and 95%, respectively, at a significance threshold of α = 0.05. 
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Multipoint linkage analysis was performed by extending the variance components model 
described above to include the effect of a theoretical QTL, , as a component of genetic 
variance.  Multipoint identical-by-decent (IBD) probabilities across chromosomes 1 to 22 were 
estimated from genotype data of relatives via a Markov Chain Monte Carlo algorithm 
implemented in Loki (102).  Maximum likelihood methods were used to estimate  based on 
the expected covariance due to IBD probabilities between relatives at each locus along the 
chromosomes.  Significance of  was assessed by the likelihood ratio test, which compared the 
QTL model (i.e. including  as a component of variance) to the polygenic model (i.e.  = 0), 
and expressed as a logarithm of the odds (LOD) score (log
2
mσ
2
mσ
2
mσ
2
mσ 2mσ
10 of the likelihood ratio).  This test 
follows a 50:50 mixed distribution of a zero point mass and a 1-degree of freedom chi-squared 
distribution.  Empirical LOD score adjustment based on 10,000 simulated unlinked markers was 
used to guard against inflated LOD scores, which can occur due to deviations of the phenotype 
distribution from normality (104).  Power to detect linkage was low:  approximately 25% and 
40% at thresholds of LOD = 2.0 and 1.5, respectively, for a QTL explaining 25% of variance in 
rates of BMD change.   
Genetic modeling was performed in the set of all participants aged 25 to 45 years (n = 
327) as well as the subset of age-eligible men and premenopausal women (n = 292).  To assess 
whether differences in linkage results obtained from the total sample and premenopausal subset 
were due to diminished sample size (null hypothesis), or alternatively, due to inclusion of post-
menopausal women, 100 random subsets of 292 individuals (sampled without regard to 
menopausal status) were used to generate an empirical distribution of the effect of reduced 
sample size (125).  Genetic analyses were performed using the Sequential Oligogenetic Linkage 
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Analysis Routines (SOLAR) software (101);  data management, summary statistics, outliers, and 
figures were done in R (R Foundation for Statistical Computing, Vienna, Austria). 
4.4 RESULTS    
Characteristics of the 327 participants included in this study are presented in Table 4.1.  On 
average, adiposity in this sample was high (BMI > 30) in both men and women, and weight 
increased (0.82 kg/year in women and 0.45 kg/year in men) over 5.6 years of follow-up (range = 
3.5 to 8.9 years).  Distributions of yearly change in BMD (%SD/year) are shown in Figure 4.1.  
Change in BMD was calculated as the yearly difference between standardized (mean = 0, SD = 
1) BMD measurements at baseline and follow-up in order to mitigate the effects of differences 
between baseline and follow-up measurements. 
Genetic and environmental influences on BMD change for participants aged 25 to 45 
years are shown in Table 4.2.  Significant heritability of BMD change was observed for the total 
hip (h2r = 0.34, p = 0.01), radius (h2r = 0.27, p = 0.03), and ulna (h2r = 0.35, p = 0.01).  Modest 
heritability was observed for the femoral neck (h2r = 0.22, p = 0.06).  In contrast, BMD change of 
the total spine was not heritable.  As expected, women who entered menopause during the 
interim between visits experienced significantly faster bone loss at the femoral neck, total hip, 
and total spine; however, this relationship was not observed for sites of the forearm (Table 4.3).  
Interestingly, women experienced slower rates of bone loss than did men (i.e. female sex was 
positively correlated with BMD change) for all sites except ulna.  Bone loss increased with 
increasing age only at the forearm sites.  The cumulative amount of variation attributable to 
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measured covariates differed greatly between skeletal sites, ranging from 5% for the ulna to 24% 
for the femoral neck.   
 
Table 4.1.  Mean (SD) population characteristics 
variable all (SD) women (SD) men (SD) 
sample size, n 325  210  115  
follow-up (years) 5.6 (0.7) 5.5 (0.7) 5.6 (0.7) 
age (years) 34.4 (5.9) 34.6 (5.8) 34.2 (6.1) 
anthropometrics       
height (cm) 162.2 (8.8) 157.4 (6.1) 170.8 (6.2) 
weight (kg) 80.4 (20.7) 75.9 (19.2) 88.6 (20.8) 
BMI (kg/m2) 30.5 (7.0) 30.6 (7.4) 30.3 (6.3) 
annual weight gain (kg/year) 0.69 (1.39) 0.82 (1.40) 0.45 (1.35) 
annual change in BMI (kg/m2/year) 0.27 (0.52) 0.33 (0.55) 0.15 (0.45) 
medical       
diabetes (%) 10.7  - 10.4  - 11.2  - 
pre-menopausal (%)  -  - 95.3  -  -  - 
oral contraceptives (%)  -  - 20.9  -  -  - 
interim entrance into menopause (%)  -  - 9.2  -  -  - 
lifestyle       
alcohol consumption (%) 50.8  - 44.5  - 62.1  - 
smoking history (%) 20.8  - 19.4  - 23.3  - 
baseline BMD (g/cm2)       
femoral neck 0.89 (0.13) 0.87 (0.12) 0.92 (0.13) 
total hip 0.99 (0.15) 0.96 (0.13) 1.05 (0.15) 
radius (ultradistal)  0.50 (0.07) 0.47 (0.05) 0.55 (0.06) 
ulna (33%) 0.71 (0.08) 0.66 (0.05) 0.79 (0.06) 
total spine 1.05 (0.12) 1.05 (0.12) 1.04 (0.13) 
follow-up BMD (g/cm2)       
femoral neck 0.87 (0.12) 0.86 (0.12) 0.89 (0.13) 
total hip 1.01 (0.14) 0.99 (0.13) 1.06 (0.14) 
radius (ultradistal)  0.49 (0.06) 0.47 (0.05) 0.53 (0.07) 
ulna (33%) 0.77 (0.08) 0.72 (0.05) 0.85 (0.07) 
total spine 1.03 (0.12) 1.04 (0.11) 1.01 (0.12) 
 
Because menopause is widely acknowledged to have profound effects on bone loss, 
genetic and environmental influences on BMD change were also assessed after excluding 35 
women who reported having undergone menopause during the years of follow-up.  Heritability 
estimates in this subset were greater for the femoral neck (h2r = 0.29, p = 0.05) and total hip (h2r 
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= 0.49, p = 0.001), similar for the ulna (h2r = 0.39, p = 0.01) and spine (h2r = 0.0, p = 0.50), and 
lower for the radius (h2r = 0.25, p = 0.06).  Standard errors and cumulative variance due to 
covariates (excluding the effect of menopause) were essentially unchanged. 
 
 
Table 4.2.  Residual heritability of BMD change 
 
trait n h2r SE p-value 
femoral neck 300 0.22 0.16 0.06 
total hip 300 0.34 0.17 0.01 
radius (ultradistal) 313 0.34 0.16 0.00 
ulna (33%) 321 0.35 0.17 0.01 
total spine 295 0.00  - 0.50 
 
h2r = residual heritability  
 
 
Table 4.3.  Relationship between BMD change and covariates:  beta-coefficients (p-value) 
 
  femoral neck total hip radius (ultradistal)  ulna (33%) total spine 
n 300  300  313  321  295  
R2 0.24  0.16  0.14  0.05  0.14  
sex 1.9 a (0.023) 2.2 (<0.001) 5.1 (<0.001)  - (0.367) 3.8 (<0.001) 
age  - b (0.738)  - (0.284) -0.2 (0.002) -0.2 (<0.001)  - (0.489) 
meno c -4.4 (0.008) -3.3 (0.009)  - (0.699)  - (0.310) -5.5 (0.001) 
BMI 5.1 (<0.001) 0.2 (<0.001) -0.1 (0.097) -0.1 (0.036) -0.1 (0.045) 
ΔBMI 0.6 (<0.001) 3.0 (<0.001) 1.4 (0.064)  - (0.141)  - (0.642) 
BMD -15.9 (<0.001)  -  (0.663) 14.9 (0.045)  - (0.214) -10.6 (0.002) 
 
R2 = proportion of variance due to covariates  
beta-coefficients are interpreted as %SD/year per unit of covariate 
a effect of female sex with respect to male sex 
b only covariates with significant effects at α = 0.1 are included in genetic models 
c meno = entrance into menopause during interim between baseline and follow; 
  ΔBMI = yearly change in BMI during interim (kg/m2/year);  
  BMD = site-specific baseline BMD (g/cm2) 
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Figure 4.1.  Distributions of change in BMD (%SD/year) for (i) femoral neck, (ii) total hip, (iii) radius, (iv) ulna, 
and (v) total spine.  Grey bars represent the total sample (women + men); black bars represent women. 
 
Figure 4.2 depicts whole genome multipoint linkage scans for BMD change of the 
femoral neck, total hip, radius, and ulna (but not spine because change at this site was not 
heritable).  A significant QTL was observed on chromosome 1q23 at 151 cM for femoral neck 
BMD change (LOD = 3.6, unadjusted p = 0.00002, Figure 4.3).  A suggestive QTL was observed 
on chromosome 11p14-15 at 31 cM for ulna BMD change (LOD = 2.5, unadjusted p = 0.0003).  
No other chromosomal regions exhibited evidence of linkage at LOD > 1.5 in the entire sample.  
In the subset of men and premenopausal women, linkage was diminished for the observed QTLs 
(LOD = 2.9 on chromosome 1, LOD = 2.1 on chromosome 11) and an additional suggestive 
QTL was identified for radius (LOD = 2.9 on chromosome 6q26-27 at 189 cM, unadjusted p =  
0.00006) (results not shown).  
To verify the robustness of our chromosome 1 QTL and determine whether the decrease 
in LOD score in the subset of men and premenopausal women was due to reduced sample size, 
or heterogeneity specific to postmenopausal women, we generated an empirical distribution for 
100 subsets in which 35 (10.7%) individuals were excluded at random.  The mean maximum 
LOD score across all leave-35-out subsets was 3.0 (at position 151 cM) which is not significantly 
different (p = 0.45) from our observed LOD = 2.9 in the subset of individuals that included only 
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men and pre-menopausal women.  Thus, the observed decrease in evidence of linkage in the 
subset was likely due to a reduction in sample size alone and not evidence for heterogeneity. 
 
 
 
Figure 4.2.  Genome-wide multipoint linkage scans 
 
 
 
Figure 4.3.  Multipoint LOD score profile for femoral neck BMD change on chromosome 1 in total sample (solid 
line) and subset of men and premenopausal women (dashed line) 
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4.5 DISCUSSION 
Cross-sectional and longitudinal studies have shown that BMD declines in young men and 
women of European (92,138,140) and African ancestry (17), and that most of this change results 
from loss of trabecular bone density.  One method by which to increase our understanding of the 
mechanisms influencing early bone loss is to determine that such longitudinal loss is heritable 
and subsequently identify the specific genes involved.   
In this study we show substantial variation in the individual rates of early areal BMD loss 
at the femoral neck, total hip, radius, and ulna, and estimate that genetic factors are responsible 
for up to 35% of this variation.  In contrast, we found that early bone loss at the lumbar spine 
was not heritable.  Although our results include both men and women, they are consistent with 
those of Hui et al. (94) who reported heritability of femoral neck BMD in pre-menopausal 
women only.  Our estimates of heritability of early bone loss are also similar, with a few 
exceptions, to those for bone loss among older individuals at several skeletal sites (95,116).  
Together, this body of evidence suggests that rates of BMD loss are heritable for many skeletal 
sites, in both men and women, young and old.   
Our linkage scan yielded two putative QTLs influencing bone loss in young adults.  The 
QTL for change in femoral hip BMD on chromosome 1q23 (LOD = 3.6) has been reported to 
influence variation in peak spine BMD in several (37,45,50,58), but not all (141), previous cross-
sectional studies; specifically, this QTL was not observed in our Mexican American sample for 
either peak BMD (42) or BMD loss in older individuals (116). These possibly contradictory 
results could be explained by a QTL influencing BMD change, rather than peak BMD, in an age-
specific manner.  For example, linkage studies for peak BMD (37,45) and BMD change in young 
individuals are well-suited to detect a genetic regulator of early BMD change, whereas linkage 
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(42) and exclusion (141) analysis for BMD in mixed-aged samples, and linkage analysis for 
BMD change in older samples (116), are not.   
The one-LOD unit support interval for the femoral neck QTL on chromosome 1q23 
ranges from 146 to 155 cM (approximately 133 Mbp to 157 Mbp) in a gene-rich region 
containing 429 known or hypothetical genes.  In particular, this region includes 
BGLAP/osteocalcin, which has well known effects on bone formation (111,142), and IL6R, for 
which previous studies have shown genetic association to BMD (143), and linkage to BMD and 
osteopenia (70).  Additionally, a zinc/iron transporter (SLC39A1; mouse homolog expressed in 
osteoblasts of developing bone) (144), and 17 calcium binding proteins (S100A1-A7, -A7.1, -
A7.2-A14, -A16) are contained in the support interval.  One or more of these genes, or other 
linked loci, may contribute to our observed linkage signal.   
We also obtained suggestive evidence for a QTL influencing early BMD change at the 
ulna on chromosome 11p14-15 (LOD = 2.5).  Due to its position, this QTL is likely distinct from 
those detected in previous studies for peak BMD of the spine at 11q12-13, the LRP5 locus 
(41,46), or 11q23 (49).    The one-LOD unit support interval for our suggestive QTL ranges from 
22 to 42 cM (approximately 14 to 25 Mbp) covering 88 genes.  Notable genes in this region are 
calcitonin alpha (CALCA), beta (CALCB), and pseudogene (CALCP).  Calcitonin is a thyroid 
hormone regulating serum calcium levels, and has known inhibitory effects on the resorptive 
activity of osteoclasts (145).  Calcitonin could also be involved in early BMD change and is a 
reasonable positional candidate gene for BMD change. 
We speculate that because the femoral neck is comprised of both cortical and trabecular 
bone, and because growing evidence suggests that early bone loss occurs primarily in the latter 
(17,92), that observed linkage to chromosome 1q23 may be due to one or more genes affecting 
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trabecular bone loss.  On the other hand, some early loss of cortical bone does occur (92).  It is 
likely that the putative QTL on 11p14-15 affecting BMD change of 33% ulna, which is 
comprised almost entirely of cortical bone, is due to one or more genes influencing cortical loss.  
Though direct measurement of trabecular and cortical content are not available in this study, 
these hypotheses reflect recent findings in other populations (17,92), and are consistent with the 
largely uncorrelated linkage scans for different skeletal sites.   
A major strength of the current study is the combined longitudinal and family-based 
study design.  Our assessment of 5-year BMD change is better suited to elucidate the genetic 
effects of early bone loss than other cross-sectional linkage scans, and the inclusion of many 
types of relatives pairs within our extended families allows us to better model truly genetic 
effects on BMD change (as opposed to familial non-genetic effects, such household effects), than 
do studies using twins or sibships.  These strengths notwithstanding, several limitations of the 
present study need also be addressed.  First, while statistical power to detect heritability of BMD 
change was adequate, power to detect linkage at genome-wide significance was poor, and our 
sample size precluded testing for gene × sex or gene × environment interactions.  Also, 
densitometry equipment was upgraded during the follow-up interim which may have introduced 
measurement bias; however, due to the independent standardization of baseline and follow-up 
measurements and excellent agreement observed in our cross-calibration experiment, any 
unknown effects of our equipment upgrade are probably minimal.  Finally, DXA technology is 
inherently limited in its ability to detect BMD change because areal projection may not 
adequately account for the size (depth) of bone or possible change in bone size over time, and 
cannot measure trabecular and cortical content separately. 
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In conclusion, this study reports that early bone loss at several skeletal sites is heritable 
and similar in magnitude to the heritability of late bone loss.  The QTLs  for early bone loss that 
we detected on chromosomes 1q23 and, possibly 11p14-15 are among the first loci implicated in 
longitudinally-assessed BMD change, and may act as candidate regions for additional 
investigations into the genetic determinants of early bone loss.  Identification of specific genes or 
pathways influencing early BMD change may lead to better understanding of bone health and 
possible therapeutic interventions for older populations at greater risk of osteoporosis.   
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5.1 INTRODUCTION 
Osteoporosis is a condition of profound medical and public health concern in the aging 
populations, worldwide.  In the United States alone, more than 15% of women ages 50 to 59 and 
up to 70% of women over 80 years of age will be affected by this disease, contributing to 
approximately 350,000 hip fractures per year (3,146).  In addition to mounting health care costs 
and significant morbidity associated with such fractures, including decreased mobility, the 1-year 
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mortality for those experiencing osteoporotic hip fracture is almost 25% (20).  While other 
aspects of bone quality are also important, the primary indicator of bone strength and risk factor 
for osteoporotic fracture is bone mass (147)—usually quantified as bone mineral density across a 
projected area or volume—which has been shown to be highly heritable (27,28).    
Many genome-wide linkage scans have been performed to identify chromosome regions 
associated with peak bone mineral density (BMD), yielding evidence for linkage to several 
chromosomal regions (58,122).  In particular, possible quantitative trait loci (QTLs) influencing 
peak hip BMD have been mapped to chromosomes 1p (36,121), 2p (35,42), 2q (38,55), 3p (55), 
3q (55), 4q (35), 5q (45), 6p (44), 6q (42), 7p (38,55), 12p (56),13q (42), 14q (48), 15q (48,56), 
16q (38), 20p (51), 21q (44), and 22p (56).  However, few of these candidate QTLs have been 
replicated in more than one study, which may be due to (i) population differences in the genetic 
determinants and/or gene × environment interactions affecting BMD, (ii) inadequate statistical 
power to detect QTLs, or (iii) false positive linkage signals (50).  Because bone density is likely 
to be affected by a large number of genes, genetic heterogeneity—i.e. differences in the specific 
genes accounting for variation in BMD—between populations or cohorts is not surprising.  
However repeated studies in the same population may provide a means by which to distinguish 
false positives from QTLs that consistently influence BMD from one time point to another.  On 
the other hand, BMD is truly a dynamic phenotype that changes greatly throughout the lifespan, 
and the genetic factors influencing BMD may be expressed differently across age ranges (24) 
and between men and women (25,42,43,50,55,56,58,135).  Repeated measurements across 
longer periods of time, perhaps a decade or more, may serve as a means by which to investigate 
the age-specific genetic factors influencing BMD across the lifespan. 
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The San Antonio Family Osteoporosis Study (SAFOS) was designed to identify the 
environmental and genetic factors influencing BMD using data from 884 members of 34 
multigenerational Mexican-American families.  We have previously identified putative QTLs 
affecting hip BMD on chromosomes 2p, 6q and 13q in a subset of 664 individuals.  Specifically, 
we reported a suggestive linkage signal for trochanter areal BMD (multipoint LOD = 2.27) on 
chromosome 6q in both sexes.  In men (n = 259), we observed possible QTLs for femoral neck 
BMD on the telomeric region of chromsome 2p (LOD = 3.98), and for femoral neck and 
trochanter BMD on chromosome 13q (LOD = 2.51 and 3.46, respectively) (42).  Subsequent to 
these analyses, genotype data for an additional 220 study participants were obtained, and follow-
up BMD measurements were collected approximately 5.6 years after original measurements.  
Here we report an update and follow-up to our original genome-wide linkage scan including 
genome-wide linkage analysis of the total baseline sample, as well as new genome-wide linkage 
analysis of our follow-up sample.  We have used repeated BMD measurements to confirm QTLs 
influencing common variation in BMD and provide insight into possible gene × age interactions. 
5.2 METHODS 
5.2.1 Recruitment and data collection 
Participant recruitment and data collection for the SAFOS has previously been described in 
detail (30).  In brief, a population-based sample of Mexican American probands, along with their 
spouses and all first, second, and third degree relatives of probands and spouses, were invited to 
participate in the study (n = 884, 34 families, 341 men, 543 women).  Eligible probands had to 
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be between 40 and 60 years of age with large families in the San Antonio area.  All available 
participants were enrolled without regard to prior medical history.  Approximately 82% of the 
original SAFOS participants were available for a follow-up visit (265 men, 459 women), along 
with an additional 163 new recruits. 
 Areal BMD measurements of the proximal femur and whole body were assessed via 
dual-energy x-ray absorbtiometry (DXA) during a baseline examination (Hologic 1500W, 
Hologic, Inc., Bedford, MA) and again at a follow-up reexamination (Hologic 4500W) 3 to 8 
years later.  Cross-calibration of DXA scanners showed near-perfect agreement between 
machines (R2 > 99.8%, p < 10-13 for femoral neck and total hip) (116).   
As described in detail elsewhere (30,116), demographic, anthropometric, reproductive, 
medical and lifestyle variables were also measured during the baseline and follow-up exams.  
Based on our previous reports (30,116), we included the following covariates in this study:  
demographic covariates including age at examination, age2, sex, age × sex, age2 × sex; 
anthropometric covariates including body mass index (BMI; kg/m2); reproductive covariates 
including menopausal status (defined as surgical menopause or >12 elapsed months without 
menstrual period), use of oral contraceptives; medical covariates including diabetes status 
(assessed by self-report, current use of antidiabetic medication, or glucose tolerance test); and 
lifestyle covariates including current alcohol consumption, current smoking, and supplemental 
calcium intake (yes/no as assessed by self-report).   
Genotyping for SAFOS was carried out as previously described in detail (42).  460 highly 
polymorphic microsatellite markers across all autosomes were genotyped, and genetic maps were 
assembled via the program CRI-MAP (120) and confirmed from deCode (deCODE genetics, 
Reykjavik, Iceland).  Mean inter-marker distance was 7.6 cM (Haldane).    
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5.2.2 Analytical methods 
An autosome-wide QTL linkage scan for baseline hip BMD was previously reported for a subset 
of 664 study participants from 29 families (42).  The purpose of the present analysis is to 
perform an updated linkage scan for hip and whole body BMD on all 884 participants in the 
baseline SAFOS sample, and to perform an initial linkage scan for hip and whole body BMD in 
the follow-up sample.  Prior to genetic analyses, the distributions of BMD measurements and 
covariates were examined, and all observations in excess of 4 standard deviations from 
phenotype means were omitted (0 to 6 exclusions per phenotype).  To reduce the suite of 
covariates (enumerated above) included in genetic analyses, we performed bidirectional stepwise 
multiple regression using Akaike information criterion.  Covariates were removed or retained on 
a bone site-specific basis.  Data management and preliminary manipulations were performed in 
the R environment for statistical computing (R Foundation for Statistical Computing, Vienna, 
Austria).  
Variance components genetic modeling was employed to partition phenotype variation in 
BMD into components attributable to measured covariates, the additive genetic effects, and the 
residual error (101).  Model parameters were estimated using pedigree-based maximum 
likelihood methods (i.e. while conditioning on the covariance structure of the family data). 
Statistical significance of each parameter was calculated by comparing the full (i.e. including all 
parameters) and reduced (i.e. constraining the parameter of interest) models via the likelihood 
ratio test, which follows a chi-squared distribution with one degree of freedom for individually 
testing covariates, and a 50:50 mixture of a point mass at zero and a 1-degree of freedom chi-
squared distribution for testing genetic parameters.  Environmental covariates that were 
statistically significant at a liberal threshold of alpha < 0.1 were retained in the genetic models to 
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reduce the amount of phenotypic variation not attributable to genes.  The significance of the 
additive polygenic component was assessed by comparing maximized polygenic and sporadic 
phenotype models, which were simultaneously adjusted for covariates.  The total phenotypic 
variation explained by covariates was determined by comparing models including and excluding 
all retained covariates.  Genetic modeling was performed for the total sample and sex-specific 
sub-samples.   
Because previous analyses identified sex-specific QTLs affecting hip BMD (42), we 
expanded this variance components modeling approach to test for evidence of sex-specific 
additive genetic variances in BMD.  Modeling and hypothesis testing for sex-specific genetic 
effects has previously been described in detail (25).   In brief, we allowed genetic variances to 
differ between men and women when modeling BMD in the total sample.  Two specific 
hypotheses were then tested in this expanded model:  (i) whether the magnitude of genetic 
variance (σ2G) was equal between men and women, and (ii) whether the inter-sex genetic 
correlation (ρG, i.e. extent to which the additive genetic effect on BMD in men correlates with 
that in women) (148) was equal to one.  Unequal genetic variances would imply that genes 
account for more phenotypic variation in one sex than the other.  Inter-sex genetic correlation 
significantly less than one would imply that different suites of genes are contributing to BMD 
variation in men and women.   
Autosome-wide linkage analyses were performed within the same variance components 
framework, which modeled BMD variation as a function of effects due to a putative QTL 
component in addition to the previously enumerated components.  Both two-point and multipoint 
linkage analyses were performed; multipoint identity-by-descent (IBD) probabilities were 
calculated via the Markov Chain Monte Carlo algorithm as implemented in Loki (102).  The 
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significance of the QTL component at a given locus was determined by comparing the QTL 
model to the polygenic model, and is expressed as a LOD score.   
To remedy the potential consequence of phenotype distribution (i.e. deviations from 
multivariate normality) on calculated LOD scores, 10,000 simulations of an unlinked marker 
were performed to determine the empirical LOD score distribution for each phenotype.  Linear 
LOD score adjustments according to the empirical distribution were then applied to our findings 
for phenotypes showing inflated evidence of linkage (104).  LOD score adjustments were not 
applied for phenotypes lacking inflated evidence of linkage.  In other words, LOD score 
adjustments were conservatively applied to only reduce LOD scores, but not to increase them.   
Because genetic effects on BMD may differ by sex and age groups, heritability 
assessment and linkage scans were performed for baseline and follow-up BMD measurements in 
the total sample and sex-specific subsets, as well as the subsets of individuals >45 and <45 years 
of age.  Analyses were limited to individuals with available data for the BMD phenotype of 
interest and all retained covariates.    Variance components modeling was carried out using the 
Sequential Oligogenetic Linkage Analysis Routines (SOLAR) software (101).  
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Table 5.1.  Population characteristics at baseline and follow-up 
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5.3 RESULTS 
Population characteristics for the baseline and follow-up samples are summarized in Table 5.1.  
Of the original sample of 884 participants, 724 (approximately 82%) were reenrolled for a 
follow-up visit along with an additional 163 new recruits (total follow-up n = 887).  On average, 
this population was obese (BMI > 30) and experienced weight gain (2.4 kg) during the interim 
between exams.  The prevalence of diabetes and use of calcium supplements also increased, 
whereas the number of current smokers decreased during the years between baseline and follow-
up.  
As expected, residual heritability was similar for baseline and follow-up measurements of 
BMD of the proximal femur and total body, ranging from 0.31 to 0.76 (Table 5.2).  Measured 
environmental covariates accounted for between 10% and 47% of phenotypic variation.  
Environmental correlates of BMD in this population have previously been discussed in detail 
(30); in general, suites of covariates were similar for baseline and follow-up BMD and included 
age, age2, sex, age × sex, age2 × sex, BMI, and menopausal status, among others (Table 5.3). 
Together, genes and measured environmental covariates explained 64% to 86% of total 
phenotypic variation.   
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 Table 5.2.  Heritable, environmental, and residual error components of BMD variance at baseline and follow-up 
examinations for the total sample, men, women, subset >45 years of age, and subset <45 years of age 
 
  baseline       follow-up       
  n heritable environ error n heritable environ error 
total sample         
femoral neck 829 0.35 0.39 0.26 741 0.41 0.31 0.28 
trochanter 829 0.40 0.30 0.29 741 0.53 0.19 0.27 
intertrochanter 829 0.33 0.38 0.28 809 0.39 0.32 0.29 
total hip 829 0.33 0.40 0.27 808 0.43 0.34 0.23 
whole body 823 0.31 0.46 0.23 784 0.48 0.32 0.20 
men         
femoral neck 325 0.49 0.30 0.21 299 0.58 0.28 0.14 
trochanter 325 0.60 0.11 0.28 299 0.64 0.15 0.21 
intertrochanter 325 0.58 0.22 0.20 299 0.54 0.21 0.25 
total hip 325 0.57 0.22 0.20 299 0.61 0.22 0.17 
whole body 322 0.60 0.14 0.26 290 0.72 0.10 0.18 
women         
femoral neck 504 0.42 0.40 0.19 442 0.35 0.32 0.33 
trochanter 504 0.55 0.27 0.18 442 0.61 0.18 0.21 
intertrochanter 504 0.37 0.36 0.28 510 0.47 0.30 0.24 
total hip 504 0.39 0.37 0.24 509 0.45 0.35 0.20 
whole body 501 0.33 0.37 0.30 494 0.56 0.33 0.11 
>45 years of age         
femoral neck 339 0.49 0.31 0.19 273 0.32 0.32 0.36 
trochanter 339 0.55 0.33 0.12 274 0.68 0.32 0.00 
intertrochanter 339 0.41 0.42 0.16 274 0.36 0.38 0.26 
total hip 339 0.44 0.43 0.13 274 0.44 0.39 0.17 
whole body 333 0.35 0.47 0.18 259 0.39 0.38 0.23 
<45 years of age         
femoral neck 490 0.38 0.32 0.31 394 0.41 0.27 0.31 
trochanter 490 0.42 0.25 0.33 394 0.52 0.16 0.32 
intertrochanter 490 0.50 0.33 0.17 394 0.44 0.25 0.32 
total hip 490 0.44 0.35 0.21 394 0.46 0.25 0.29 
whole body 490 0.53 0.36 0.11 389 0.76 0.12 0.12 
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Table 5.3.  Environmental correlates of BMD at baseline and follow-up for total sample, men, women, subset >45 years, and subset <45 years:  
Beta coefficients (p-value) 
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Table 5.3.  (continued) 
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Interestingly, point estimates of heritability at both baseline and follow-up were generally 
greater in sex-specific subsets for both men and women than in the total sample.  This 
observation may indicate that the suites of genes influencing variation in BMD only partially 
overlap between men and women; in other words, sex-specific genetic factors may be 
influencing BMD in this population.  To further investigate this inference using the baseline data, 
we tested two specific hypotheses regarding sex-specific variances:  (i) that genetic variance was 
equal between men and women (H0: equal genetic variances), and (ii) that the inter-sex genetic 
correlation (i.e. the degree to which genes affecting BMD in men correlate with genes affecting 
BMD in women) is equal to one (H0:  genetic correlation = 1).  Table 5.4 summarizes these 
hypothesis tests for BMD of the proximal femur and total body.  We found modest evidence for 
sex-specific genes affecting BMD (i.e. ρG < 1) at the femoral neck (p = 0.04), intertrochanter (p 
= 0.06), and total hip (p = 0.06).  There was no evidence of sex-specific genes influencing 
trochanter or total body BMD (p = 0.11 and 0.37, respectively), though such genes may exist, as 
our study may not have adequate power to reliably detect genetic correlations less than one.  We 
found no evidence that the additive genetic variance differed in men and women (Table 5.4).   
 
Table 5.4.  Tests of sex-specific additive genetic effects on baseline BMD 
 
        H0:  σG.men = σG.women H0:  ρG = 1 
BMD site σG.men σG.women ρG p-value p-value 
femoral neck 9.88 8.49 0.75 0.33 0.04 
trochanter 8.51 7.84 0.81 0.46 0.11 
intertrochanter 12.08 10.77 0.79 0.91 0.06 
total hip 10.28 9.33 0.78 0.60 0.06 
whole body 7.16 5.70 0.96 0.97 0.37 
 
sigmaG.men = genetic standard deviation (i.e. square-root of genetic variance) in men;  
sigmaG.women = genetic standard deviation in women;  
rhoG = inter-sex genetic correlation 
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Table 5.5.  LOD score adjustment factors 
 
  baseline follow-up 
total sample   
femoral neck 1.16 1.17 
trochanter 1.08 1.16 
intertrochanter 1.12 1.08 
total hip 1.16 1.17 
whole body 1.12 1.12 
men   
femoral neck 1.37 1.43 
trochanter 1.37 1.42 
intertrochanter 1.51 1.41 
total hip 1.52 1.65 
whole body 1.29 1.61 
women   
femoral neck 1.15 0.96 
trochanter 1.10 0.99 
intertrochanter 1.01 0.86 
total hip 1.06 0.93 
whole body 1.05 0.96 
>45 years   
femoral neck 0.92 0.79 
trochanter 1.09 0.95 
intertrochanter 0.94 1.01 
total hip 1.19 1.05 
whole body 1.00 0.87 
<45 years   
femoral neck 1.20 1.20 
trochanter 1.08 1.13 
intertrochanter 1.20 1.00 
total hip 1.20 1.07 
whole body 1.12 1.16 
 
 
We next performed autosome-wide linkage analyses for baseline and follow-up BMD in 
the total sample, men, women and sub-samples >45 and <45 years of age, to search for overall, 
sex-specific, and age-specific loci implicated in BMD.  Although a large number of linkage 
analyses are presented, the problem of multiple testing is greatly reduced due to the high genetic 
correlation between BMD at skeletal sites (rhoG = 0.73 to 0.98).  Empirical LOD score 
adjustments were calculated from 10,000 simulations of a fully-informative unlinked marker, 
and are shown in Table 5.5.  LOD score adjustment factors less than 1.0, indicating inflated 
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evidence of linkage, were applied to the findings presented herein.  LOD score adjustments 
greater than 1.0 (i.e. indicating deflated evidence of linkage) were not applied; therefore, our 
results are likely conservative.   
 Autosome-wide multipoint linkage results are shown in Figure 5.1 for the total sample, 
men, and women, and Figure 5.2 for the subsets <45 years and >45 years of age.  Putative QTLs 
(LOD > 2.0) at baseline and/or follow-up for proximal hip and whole body BMD were observed 
on several chromosomes (Table 5.6).  Some of these chromosomal regions exhibited strong 
evidence of linkage at baseline or follow-up, but not both, suggesting that the QTL may be a 
false positive.  For example, on chromosome 1q, linkage was observed for trochanter BMD in 
the total sample and subset <45 years of age (LOD = 2.22 for both) at follow-up, but not baseline 
(LOD = 0.59 and 1.58, respectively).  Similarly, a likely false positive for femoral neck BMD 
located on chromosome 2p was observed in men at baseline (LOD = 3.04), but not follow-up 
(LOD = 1.05).  Other non-replicated findings were observed on chromosome 10p (LOD = 2.45 
and 2.32 at follow-up and 1.27 and 1.03 at baseline for intertrochanter and total hip BMD, 
respectively, in women), chromosome 7 (LOD = 2.71 at follow-up and 1.28 at baseline for 
intertrochanter BMD in the total sample), chromosome 11p (LOD = 3.37 at follow-up and 1.02 
at baseline for whole body BMD in women), and chromosome 11q (LOD = 2.34 at follow-up 
and 0.40 at baseline for whole body BMD in women).  One suggestive signal on chromosome 8 
previously reported for baseline femoral neck BMD in a sub-sample of men (42) showed no 
evidence for linkage (LOD < 2.0) in the expanded baseline or follow-up samples.   
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 Figure 5.1.  Multipoint linkage analysis of baseline and follow-up BMD in the total sample (black line), men (blue line), and women (red line) 
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 Figure 5.2.  Multipoint linkage analysis of baseline and follow-up BMD in the subset <45 years (red) and >45 years (blue) of age 
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Table 5.6.  Maximum LOD scores (>2.0) for chromosomes exhibiting linkage to baseline and/or follow-up BMD 
chromosome/site sample baseline follow-up Kammerer et al. (42) 
1     
trochanter total 0.59 2.22 0.70 
trochanter <45 years 1.58 2.22  - 
2     
femoral neck men 3.04 1.05 3.98 
trochanter women 2.37 1.87 1.47 
intertrochanter women 2.62 1.10  - 
whole body men 1.90 2.30  - 
3     
femoral neck men 2.04 1.84 1.81 
trochanter women 1.86 2.29 0.66 
intertrochanter women 1.32 2.07  - 
6     
trochanter total 2.17 0.75 2.27 
intertrochanter total 2.11 2.06  - 
intertrochanter women 2.99 1.76  - 
total hip women 2.79 1.60  - 
total hip <45 years 0.89 2.29  - 
whole body total 2.22 1.20  
whole body women 2.79 1.65  - 
whole body <45 years 3.04 2.40  - 
7     
intertrochanter total 1.28 2.71  - 
8     
femoral neck men 1.65 1.08 2.15 
10     
intertrochanter women 1.27 2.10  - 
total hip women 1.03 2.16  - 
11     
whole body women 1.02 3.24  - 
whole body women 0.40 2.25  - 
12     
intertrochanter <45 years 2.10 0.61  - 
total hip >45 years 2.53 0.78  - 
total hip <45 years 2.29 0.91  - 
13     
femoral neck men 2.04 1.35 2.51 
trochanter men 2.93 1.93 3.46 
trochanter <45 years 2.50 1.67  - 
intertrochanter men 2.75 2.24  - 
total hip men 2.90 2.16  - 
20     
intertrochanter <45 years 2.27 1.50  - 
 
Bold indicates LOD > 2.0 for both baseline and follow-up samples 
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  In contrast, some chromosomal regions exhibited consistent evidence of linkage at 
baseline and follow-up, or across multiple skeletal sites.  The putative QTL on chromosome 6q, 
for example, showed suggestive evidence of linkage for trochanter, intertrochanter, total hip, and 
whole body BMD at baseline and/or follow-up in the total sample, women, and subset <45 years 
of age, with the greatest signal occurring for whole body BMD in the subset <45 years of age 
(LOD = 3.04 for baseline and 2.40 for follow-up).  Likewise, chromosome 13q showed 
consistent evidence of linkage in men for all sites of the proximal femur, as well as in the subset 
<45 years for trochanter BMD.  A broad region on chromosome 3p showed modest evidence of 
linkage in the total sample, men, and women, for various sites of the proximal femur, though no 
signal >2.0 was observed on chromosome 3p for both baseline and follow-up BMD at any site or 
in any sample; the cumulative evidence of linkage to this broad region hints that a QTL may or 
may not be present. 
5.4 DISCUSSION 
We conducted an autosome-wide linkage scan for hip and whole body BMD in the SAFOS 
population for an expanded sample of baseline measurements and a largely overlapping sample 
of follow-up measurements.  Our motivations were to jointly determine if previously identified 
putative and suggestive QTLs for common variation in hip BMD could be re-substantiated after 
five years of follow-up and to search for additional QTLs that previously went undetected.  We 
hypothesized that repeated measurements could help identify as possible false positive QTLs the 
regions showing linkage at one, but not both, time points. 
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Because phenotypes that vary across time may be due, in part, to genetic effects that vary 
across time, study designs that capture the dynamic nature of these phenotypes and that are better 
equipped to identify gene × age interactions are needed.  Previous work has demonstrated the 
strengths of using repeated measurements in genetic studies.  Some investigations compared 
linkage results from serial measurements of BMI to show that the effects of genes may vary 
across time (125,149), while others used longitudinal BMI measurements to form composite 
phenotypes reflecting trends over time (150,151).  Other studies similarly used longitudinal 
measurements to investigate gene × age interactions affecting blood pressure (152) and change in 
lipoprotein risk factors over time (153).  Taken together, these studies demonstrate the value of 
using longitudinal data in linkage analysis to help uncover genetic loci implicated in common 
disease.  While the present study used repeated measurements to investigate genetic factors 
affecting areal BMD, others have used two-stage designs with expanded samples to confirm 
BMD linkage signals and increase power to detect new signals (40,49).  Such designs may be 
particularly beneficial for dynamic phenotypes such as BMD. 
Our analyses yielded evidence of two suggestive QTLs, on chromosomes 6q and 13q, 
which showed linkage in both baseline and follow-up samples, and for multiple skeletal sites.  
The 6q region (located at 150 to 170 Mbp on the physical map) contains 152 known or 
hypothesized genes, including a promising candidate for the observed signal, the estrogen 
receptor 1 gene (ESR1).  ERα, the protein product of ESR1, is expressed in osteoblasts and 
osteoclasts, and may be involved in bone homeostasis (154,155).  Association between 
polymorphisms in the ESR1 gene and BMD of the hip and spine has previously been reported in 
numerous populations (62,156,157), though it is unclear based on association studies whether the 
effect magnitude of ESR1 could account for the strong linkage peak observed on chromosome 6.   
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The implicated region on 13q (located at 40 to 75 Mbp on the physical map) contains 187 
known or hypothesized genes, among which are two biologically plausible candidate genes:  
osteoprotegerin ligand (TNFSF11) and chondromodulin I (LECT1).  TNFSF11 is expressed in 
skeletal regions undergoing ossification and remodeling, and thought to promote bone loss 
through its actions as an osteoclast differentiation and activation factor (158,159).  LECT1 is a 
cartilage-specific glycoprotein that induces chondrocyte development.  Mice lacking LECT1 
exhibit increased BMD, reduced bone resorption (160), and vascular calcification (161).  
TNFSF11, LECT1, or other genes in this region may be responsible for the linkage signal 
observed on 13q in men. 
Other genomic regions (i.e. on chromosomes 1q, 2p, 2q, 3p, 7q, 10p, 11p, 11q, 12, 20q) 
were implicated in BMD at one or more skeletal sites, but did not show consistency (at LOD > 
2.0) between baseline and follow-up samples.  One explanation for inconsistent results is 
spurious linkage at one time point.  Such is the likely case for chromosome 2p in men, where the 
strong signal in the baseline sample (LOD = 3.04) was greatly diminished in the follow-up 
sample (LOD = 1.05).  Other possible causes for non-replicated linkage results are small effect 
size (whereby power to detect linkage at a threshold of LOD = 2.0 is limited) and gene × age or 
menopause interaction (whereby the mean age difference between baseline and follow-up 
samples attenuates power to detect linkage).  Such explanations are reasonable for modest 
signals demonstrating some degree of consistency, albeit not at the LOD = 2.0 threshold used in 
this study.  For example, chromosome 2q shows suggestive linkage to trochanter BMD in 
women in the baseline sample (LOD = 2.37) and weak linkage in the follow-up sample (LOD = 
1.87); thus, the joint interpretation of baseline and follow-up results is not entirely clear.  These 
and similar results are consistent with the situation of a true QTL for which we have limited 
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power to detect linkage at LOD = 2.0.  Moreover, recent work has shown that the variable rates 
of change in BMD over time among individuals are heritable in older (>45 years) (116), 
postmenopausal (95) and premenopausal (94) populations, but studies of peak BMD (including 
this one) assume sample-wide rates of change.  Thus, genetic factors affecting BMD change may 
attenuate the apparent role of genes on peak BMD, and may do so differently depending on the 
age of the sample.    
  Prior to conducting our linkage analyses, we tested for evidence of sex-specific additive 
genetic effects influencing variation in hip and whole body BMD.  Our findings of modest 
evidence for sex-specific genes are consistent with a growing body of previous work 
demonstrating varying degrees of sex-specificity for genetic regulation of BMD in humans 
(17,25,30,42,50,162,163) and mice (164).  The lack of evidence for sex-specific genes 
influencing BMD at some anatomical bone sites may be due to insufficient power in our study to 
detect such effects.  By modeling genetic variance independently in men and women, we greatly 
diminished the number of informative relative pairs because only same-sex relatives were 
utilized.  Additionally, our analyses pooled subjects across a wide range of ages, thereby limiting 
our ability to detect possible sex-specific effects which differ across age cohorts.  For example, 
sex-specific genes affecting a specific age cohort, such as bone acquisition in younger or bone 
loss in older individuals, are unlikely to be detected by our methods.  Therefore, for anatomical 
sites where no sex-specificity was detected, the cumulative effect of sex-specific genes may 
simply be too small to distinguish from the effect of non-sex-specific genes.  Interestingly, while 
we observed some evidence for sex-specific genes influencing BMD, we found no evidence that 
the magnitude of the total effect of genes differed between sexes.  In other words, the impact of 
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genetics on BMD was similar between men and women, though the specific genes involved may 
differ.   
Our linkage analyses for baseline and follow-up measurements of BMD are consistent 
with the hypothesis that some genes contribute to BMD in both sexes, whereas other genes are 
sex-specific.  The putative QTL on chromosome 13q was observed only in men, suggesting an 
interaction between sex and the effects of genes in this region.  The linkage signal on 
chromosome 6q for hip and whole body BMD, on the other hand, was observed for the total 
population, possibly indicating the presence of a putative QTL affecting BMD in both sexes.  
However, this QTL was also observed in women, but not in men, indicating that effects in 
women (who make up the greater part of the total sample) may be driving the observed signal in 
the combined sexes sample, whereas the effect in men may be more modest.  Moreover, because 
this QTL affects whole body BMD, it may correspond to a gene with system-wide (rather than 
site-specific) affects on bone metabolism.  ESR1, in this region, is likely to have system-wide 
effects, especially in women.   
A major strength of this study is the repeated measurements of BMD which has allowed 
us to place greater confidence in replicated linkage signals, and cast doubt on non-replicated 
signals.  However, defining and interpreting replication is problematic, requiring further 
investigation to distinguish false positives from situations where true QTLs are observed at a 
single time point.  Our family data is sufficiently large to search for QTLs influencing BMD 
overall and within sex or age cohorts.  However, we have insufficient power for testing other 
gene × environment interactions or for sub-dividing into more homogenous groups (e.g. post-
menopausal women).  Despite these limitations, and owing to the aforementioned strengths, this 
study has successfully confirmed our previously reported linkage signals on chromosome 6q and 
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13q, implicating these loci in the regulation of BMD in Mexican Americans.  Further 
investigation of these regions, including inquiry into the candidate genes ESR1, TNFSF11, and 
LECT1 may yield better understanding of the biological processes governing common variation 
in BMD, and could lead to new insights for the risk assessment and treatment of osteoporosis.   
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6.1 INTRODUCTION 
Vertebral fractures are exceedingly common:  the lifetime risk of clinically diagnosed vertebral 
fracture is 16% in white women (5% for men), but because many fractures of the spine go 
undiagnosed, the actual rates are much higher (105).  In a cohort of US women >50, the total 
prevalence of one or more vertebral fractures was 25% (165).  Similar rates of vertebral fractures 
in postmenopausal women have been shown for other populations (105), reflecting the 
substantial public health impact of this condition.  While not as devastating as hip fractures, 
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vertebral fractures can initially be very painful and lead to loss of height, kyphosis, poor posture, 
decreased mobility, and chronic pain.  In addition to the physical detriment of spine fracture, 
dependency due to fracture and the related negative emotional impact may greatly decrease 
quality of life (105).  As human longevity increases, the incidence of osteoporotic fractures and 
economic burden of treatment are also expected to rise (4), thus the problem of osteoporosis will 
continue to grow.  
Like fractures of other skeletal sites, risk of vertebral fracture is due, in part, to bone 
strength, which is largely determined by bone mineral density (BMD).  A number of 
environmental correlates of spine BMD have been described, including sex, age, height, weight, 
family history of fracture, menopause, estrogen use, and physical activity (30,105).  In addition 
to environmental factors, genes also play a major role in determining spine BMD 
(17,22,24,25,30).  Many linkage analyses have been performed to search for specific quantitative 
trait loci (QTLs, i.e. genomic regions influencing a continuous trait) affecting spine BMD in 
numerous populations.  Chromosomal regions possibly harboring QTLs for spine BMD have 
been mapped to regions all over the genome, including: 1p (53), 1q (33,37,45,50,134), 2p 
(35,134), 3p (50,54,55), 3q (135), 4q (34), 5q (38), 6p (51), 7p (49,121), 11q (41,49), 12q 
(34,44), 13q (34,38,55), 14p (134), 14q (43), 15q (55), 16q (54), 17p (51,56), 18p (51,135), 20p 
(49,51), 20q (135), and 21q (50).  Few of these QTLs have been replicated in more than one 
study, possibly due to false positives, genetic heterogeneity, differences in gene × environment 
interactions, or differences in demography, environmental risk factors, and ancestry across study 
samples.  Analysis of repeated BMD measurements in the same population may aid in filtering 
possible false positive signals from those consistently observed across multiple time points.  This 
approach has been employed in our study of the environmental and genetic causes of spine 
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BMD.  Based on our previous results indicating differences in genetic architecture of bone loss 
among <45 and >45 years (Chapters 3 and 4), as well as differences between men and women 
(Chapter 5), we also performed analyses of spine BMD in these subsets. 
6.2 METHODS 
6.2.1 Recruitment 
The San Antonio Family Osteoporosis Study (SAFOS) is a longitudinal study of the 
environmental and genetic determinants of bone strength-related phenotypes in an unselected 
sample of 34 multigenerational families of Mexican Americans.  Recruitment and data collection 
has been described previously for baseline and follow-up phases of the study (30,116).  Briefly, 
Mexican American probands aged 40 to 60 years with large families in the San Antonio area, 
and all adult first-, second-, and third-degree relatives of probands and spouses were invited to 
enroll in SAFOS without regard to prior medical history.  At baseline, 853 participants (327 men 
and 526 women) with spine DXA measurements were recruited; at follow-up 3 to 8 years later 
(mean = 5.6 years), 859 participants with spine DXA measurements were recruited (686 
returning and 173 new participants; 313 men and 546 women).   
6.2.2 Data collection  
BMD was assessed for lumbar vertebrae (L1 to L4) via dual-energy x-ray absorptiometery at 
baseline (Hologic 1500W, Hologic, Inc., Bedford, MA) and follow-up (Hologic 4500W).  
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Because measures of BMD of the four lumbar vertebrae (L1-L4) are highly correlated, we 
investigated total spine BMD, calculated as the total mineral content divided by total area of L1 
to L4, in the current report.  Cross-calibration of DXA scanners used at baseline and follow-up 
showed near-perfect agreement between machines (R2 = 99.8%, p < 10-13 for femoral neck and 
total hip) (116).  Data for demographic, anthropological, reproductive, medical, and lifestyle 
variables were assessed via questionnaire at baseline and follow-up according to previously 
published protocols (30,116).  In this study, the following covariates were considered:  age 
(years), age2, sex, sex × age, sex × age2, BMI (kg/m2), menopause (yes/no defined as >12 months 
since previous menstrual cycle or surgical menopause), use of oral contraceptives (yes/no), 
diabetes (yes/no), current smoking (yes/no), current alcohol consumption (yes/no), and 
supplemental calcium intake (yes/no).  Spine BMD measurements or data on one or more 
covariates were not obtained for all participants.  Genotyping for 460 highly polymorphic 
microsatellite markers and genetic map construction (mean resolution = 7.6 cM across 
chromosome 1 to 22) has been described previously (42). 
6.2.3 Data analysis 
Distributions of total spine BMD and aforementioned covariates were assessed, and all 
observations > 4 standard deviations from phenotype means were omitted (0 to 6 exclusions per 
phenotype).  Statistically significant effects of covariates on baseline and follow-up spine BMD 
were assessed by bidirectional stepwise multiple regression analysis.  Heritability of spine BMD 
was estimated using variance components methods, which deconstruct phenotype variance into 
the effects attributable to covariates, additive genetics (based on the expected sharing of relative 
pairs), and residual error (which includes non-measured environmental and non-additive genetic 
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effects).  Maximum likelihood methods, while conditioning on the pedigree structure of the data, 
were used to estimate model parameters.  Significance of heritability and covariates were 
determined via the likelihood ratio test by comparing models retaining and excluding the 
parameter being tested.  The test statistic follows the chi-squared distribution with 1 degree of 
freedom for testing covariate effects, and a 50:50 mixed distribution of a point mass at zero and a 
chi-squared distribution with 1 degree of freedom for testing heritability.  Covariates with 
significant effects at α = 0.1 were retained in the model. 
 Multipoint linkage scans were performed by extending the variance components model 
to include the effect of a hypothetical QTL at an arbitrary genetic locus.  Multipoint identity-by-
descent (IBD) probabilities were estimated for all pairs of relatives at each genetic locus via a 
Markov Chain Monte Carlo algorithm as implemented in Loki (102).  Pedigree-based maximum 
likelihood methods were used to estimate the QTL effect based on the covariance due to IBD 
probabilities between relatives across chromosomes 1 to 22.  The significance of a hypothetical 
QTL at each locus was assessed by the likelihood ratio test comparing the QTL model to the 
polygenic model (i.e. no QTL effect), which follows a 50:50 mixed distribution with a point 
mass at zero and a chi-squared distribution with 1 degree of freedom.  Significance of a 
hypothetical QTL at each locus is reported as a logarithm of the odds (LOD) score (log10 of the 
likelihood ratio).  The possibility of inflated significance due to deviations from multivariate 
normality was checked by generating an empirical null distribution of 10,000 simulated, 
unlinked markers.  Inflated LOD scores were adjusted based on the empirical distribution 
(however, deflated LOD scores were not adjusted, therefore results may be conservative).   
Data analysis was performed for the total samples at baseline and follow-up, as well as 
subsets of men, women, participants <45 years, and participants >45 years of age.  Analyses 
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were limited to individuals with data for BMD and all retained covariates, thus sample sizes for 
genetic models are considerably smaller than the total number of participants recruited.  Genetic 
analyses were performed in the Sequential Oligogenetic Linkage Analysis Routines (SOLAR) 
software (101);  data manipulations, outlier removal, stepwise regression, and figures were done 
in R (R Foundation for Statistical Computing, Vienna, Austria). 
6.3 RESULTS    
Descriptive statistics of the SAFOS population have been presented elsewhere (30,116).  Mean 
age was 42.8 years at baseline and 47.5 years at follow-up (Table 6.1).  On average, the sample 
was obese (BMI > 30) and gained weight (2.0 kg) during the years between medical exams.  
Likewise, prevalence of diabetes increased, and spine BMD decreased, between baseline and 
follow-up.  Baseline spine BMD data were available for 853 of the SAFOS participants from 34 
families (containing 651 parent-offspring pairs, 719 siblings, and 6,455 other relative pairs); 
follow-up spine BMD measurements were available for 859 individuals (573 parent-offspring 
pairs, 684 siblings, and 5,565 other relative pairs).    
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Table 6.1.  Population characteristics:  mean (SD) 
 
  total sample     men       women     
  baseline follow-up baseline follow-up baseline follow-up 
sample size 853  859  327  313  526  546  
demographics             
age (years) 42.8 (15.9) 47.5 (14.5) 42.2 (16.6) 46.4 (14.8) 43.2 (15.4) 48.1 (14.2) 
anthropometrics             
height (cm) 162 (9.3) 162 (9.2) 170 (6.7) 171 (6.1) 157 (6.3) 157 (6.2) 
weight (kg) 80.0 (18.6) 82.0 (18.5) 86.3 (18.2) 87.8 (18.1) 76.1 (17.8) 78.7 (17.9) 
bmi (kg/m2) 30.5 (6.4) 31.3 (6.4) 29.7 (5.7) 30.0 (5.4) 31.0 (6.8) 32.1 (6.7) 
medical             
diabetes (%) 17.5  20.7  16.8  24.3  17.9  18.6  
reproductive             
pre-menopausal (%)         69.5  53.8  
oral contraceptives (%)         12.8  12.6  
lifestyle             
alcohol consumption (%) 41.9  44.5  60.2  61.1  30.5  35.0  
smoking (%) 21.6  19.2  30.0  26.6  16.4  14.9  
calcium supplement  (%) 12.6  20.8  5.3  11.5  16.7  26.2  
BMD (g/cm2)             
lumbar spine 1.03 (0.15) 1.01 (0.15) 1.06 (0.15) 1.04 (0.15) 1.01 (0.14) 1.00 (0.14) 
 
 
Table 6.2.  Environmental correlates of spine BMD:  beta-coefficients (p-values) 
 
  total sample men   women <45 years >45 years 
baseline           
sex -8.77 (9E-10)  -   -   -  -11.8 (1E-14) 
age -0.49 (1E-2) -0.60 (6E-3) 0.69 (2E-5)  -  -1.76 (7E-3) 
age2 0.01 (1E-2) 0.01 (6E-3) -0.01 (2E-10)  -  0.02 (3E-3) 
sex × age 1.23 (5E-6)  -   -   -   -  
sex × age2 -0.02 (7E-9)  -   -   -  -0.01 (2E-10) 
BMI 0.62 (3E-18) 0.70 (2E-7) 0.60 (1E-13) 0.59 (3E-14) 0.71 (2E-7) 
menopause 3.74 (2E-2)  -  3.58 (2E-2)  -    
follow-up           
sex  -   -   -   -  -13.2 (1E-12) 
age -0.55 (9E-2)  -  0.93 (4E-5)  -   -  
age2 0.01 (6E-2)  -  -0.01 (2E-7)  -   -  
sex × age 1.59 (7E-5)  -   -   -  -0.53 (6E-6) 
sex × age2 -0.02 (1E-5)  -   -   -   -  
BMI 0.43 (8E-9) 0.52 (7E-4) 0.42 (7E-7) 0.37 (6E-5) 0.53 (3E-4) 
menopause -9.03 (3E-11)  -  -7.84 (2E-6)  -   -  
calcium suppl. -2.75 (3E-2)  -   -2.44 (7E-2)  -    -   
 
beta-coefficients are interpreted as mg/cm2 of BMD per unit covariate  
sex effects are indicated for females with respect to males 
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Analyses revealed that suites of covariates with significant effects (at α < 0.1) on spine 
BMD were similar for the baseline and follow-up samples (Table 6.2).  In the total sample, the 
following determinants of baseline spine BMD accounted for 27% of phenotypic variation:  sex, 
age, age2, sex × age, sex × age2, BMI, and menopause.  In the follow-up sample, these 
covariates, with the addition of supplemental calcium intake and exclusion of sex, accounted for 
19% of phenotypic variation.  The residual heritability (h2r, i.e. the proportion of variance due 
genes after accounting for environmental covariates) of spine BMD was 0.54 and 0.61 in 
baseline and follow-up samples, respectively (Table 6.3).  Altogether, genetic and environmental 
components of variance explained 66% and 69% of variation in spine BMD, respectively, in 
baseline and follow-up total samples. 
 
 
Table 6.3.  Heritable and environmental components of variation in spine BMD 
 
          components of variance 
  n h2r (SE) p-value genetic environ. error 
baseline        
total sample 828 0.54 (0.07) 1E-18 0.39 0.27 0.34 
men 320 0.62 (0.12) 2E-09 0.57 0.08 0.35 
women 508 0.70 (0.11) 1E-10 0.47 0.34 0.20 
<45 years 486 0.78 (0.12) 3E-11 0.70 0.11 0.19 
>45 years 342 0.74 (0.16) 4E-07 0.50 0.31 0.18 
follow-up        
total sample 808 0.61 (0.08) 6E-18 0.49 0.19 0.31 
men 295 0.67 (0.17) 2E-05 0.66 0.02 0.32 
women 513 0.77 (0.10) 2E-12 0.57 0.25 0.17 
<45 years 391 0.71 (0.14) 2E-07 0.69 0.04 0.27 
>45 years 276 0.86 (0.18) 1E-05 0.69 0.20 0.12 
 
h2r = residual heritability after removing the environmental component 
environmental component of variance is due to covariates indicated in Table 6.2 
 116 
In men, age, age2, and BMI had significant effects on baseline spine BMD, whereas BMI 
alone had significant effects on follow-up spine BMD.  These covariates explained only 8% and 
2% of BMD variation, respectively.  In women, age, age2, BMI, menopause, and (in the follow-
up sample only) supplemental calcium intake significantly influenced spine BMD, together 
accounting for 34% (in the baseline sample) and 25% (in the follow-up sample) of phenotypic 
variance.  Spine BMD was highly heritable in men and women at both time points (h2r = 0.62 to 
0.77; Table 6.3).   Heritable and environmental components of variance explained 65% to 68% 
of phenotypic variation in men, and 80% to 83% in women.  Significant heritability and 
covariate effects were also detected in the sub-samples aged <45 years and >45 years. 
 
Table 6.4.  Empirical LOD score adjustment factors 
  baseline follow-up 
total sample 1.12 1.24 
men 1.12 1.58 
women 1.15 1.05 
<45 years 1.27 1.32 
>45 years 0.89 1.04 
 
 
Multipoint linkage analyses, while simultaneously incorporating the effects of 
aforementioned covariates, were performed for baseline and follow-up spine BMD in the total 
sample, men, women, and subsets <45 and >45 years of age.  To protect against inflated linkage 
signals due to deviations from multivariate normality (i.e. an assumption of the variance 
components methodology used to test for linkage), 10,000 unlinked markers were simulated to 
generate a null distribution.  Empirical LOD score adjustment factors based on this null 
distribution are shown in Table 6.4.   Adjustment factors <1.0 and >1.0 indicate inflated and 
deflated evidence of linkage, respectively.  Based on these simulations, empirical LOD score 
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adjustment was applied to linkage results for baseline spine BMD in the subset >45 years of age 
(LOD adjustment factor = 0.89).  LOD score adjustment factors >1.0 were not applied to 
findings presented herein, thus our linkage results may be conservative. 
No QTLs meeting genome-wide significance were detected for spine BMD at baseline or 
follow-up in the total sample, men, women, or age-defined subsets.  Figure 6.1 shows multipoint 
LOD scores across chromosomes 1 to 22 for all samples.  Modest evidence of linkage (at a 
threshold of LOD > 2.0) was observed for follow-up spine BMD in the total sample (LOD = 2.5, 
position 53 cM) and men (LOD = 2.6, position 62 cM) on chromosome 19p13-q13.  Two other 
loci yielded suggestive evidence of linkage:  chromosome 2q12-14 for follow-up spine BMD in 
men (LOD = 2.1, position 174 cM) and chromosome 14q11 for baseline spine BMD in the 
subset >45 years of age (LOD = 2.1, position 39 cM).  While a number of linkage scans were 
performed, the problem of multiple testing is partly alleviated due to the high genetic correlation 
between baseline and follow-up measurements of spine BMD (i.e. 99.77%).   
 
 
Figure 6.1.  Multipoint LOD scores for baseline (blue) and follow-up (red) spine BMD across 
chromosomes 1 to 22 
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 Table 6.5.  Heritable and environmental components of variance in response of spine BMD to aging (i.e. follow-up 
spine BMD adjusted for baseline spine BMD) 
 
          components of variance 
  n h2r SE p-value genetic environ. error 
total sample 666 0.09 (0.06) 0.03 0.01 0.88 0.11 
men 242 0.24 (0.14) 0.03 0.03 0.89 0.09 
women 424 0.05 (0.09) 0.28 0.01 0.87 0.12 
<45 years 392 0.09 (0.10) 0.17 0.01 0.86 0.12 
>45 years 274 0.48 (0.19) 0.002 0.05 0.89 0.05 
 
h2r = residual heritability after removing the environmental component 
 
 
In order to investigate the role of genetic factors on the response of BMD to aging, we 
additionally modeled follow-up spine BMD while adjusting for baseline spine BMD (in addition 
to other significant covariates enumerated in Table 6.2).  Table 6.5 shows results from this 
analysis, which may provide insight into the genetic basis of variation in the rates of change in 
BMD over time.  When adjusted for baseline, follow-up spine BMD was weakly heritable in the 
total population (h2r = 0.09, p = 0.03), and moderately heritable in men (h2r = 0.24, p = 0.03) and 
in the subset >45 years of age (h2r = 0.48, p = 0.002).   Estimates of heritability were not 
significantly different from zero in women (h2r = 0.05, p = 0.28) or the subet <45 years of age 
(h2r = 0.09, p = 0.17).  Multipoint linkage scans for baseline-adjusted follow-up spine BMD in 
men and the subset >45 years did not yield evidence of any QTLs (maximum LOD = 1.44 on 
chromosome 17 for men; maximum LOD = 1.58 on chromosome 11 for the subset >45 years). 
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6.4 DISCUSSION  
In this report we have estimated the heritable and environmental components of variation and 
performed autosome-wide multipoint linkage scans for spine BMD at two time points.  There 
were two primary motivations for this study.  The first was to search for environmental and 
genetic factors affecting spine BMD in one or both of the largely overlapping baseline and 
follow-up samples.  We hypothesized that the concordance or discordance of findings in baseline 
and follow-up samples may aid in interpretation of the determinants of spine BMD by placing 
greater confidence in replicated results and casting doubt on non-replicated results.  Moreover, in 
addition to the total samples at baseline and follow-up, analyses were carried out in the subsets 
of men, women, participants <45 years of age, and participants >45 years of age to find sex- and 
age-specific genetic effects on spine BMD.  The second motivation for this study was to use 
repeated measures in the intersection of baseline and follow-up samples (i.e. the subset of 
participants with data at both time points) to assess the influence of genes on variation in 5.6-
year response to aging.  By modeling follow-up spine BMD, while adjusting for baseline BMD, 
we were able to evaluate the role of genetics for changes in spine BMD with age. 
Similar to our previous reports on the genetic and envionrmental components of BMD in 
SAFOS men and women (30), these results confirm the high heritability of spine BMD for the 
total samples and age-specific subsets at baseline and follow-up, and indicate the strong effects 
of demographic variables (sex, age, and interactions), BMI, and menopause on spine BMD.  We 
show strong concordance between the heritable and environmental components of variation in 
spine BMD at baseline and follow-up.   
Linkage scans yielded no putative QTLs at genome-wide significance; the highest 
linkage signals occurred on chromosome 19p13-q13 in the total sample and in men (LOD = 2.5 
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and 2.6, respectively).  This locus has not previously been reported to influence BMD of the 
spine (or any other skeletal region).  The broad region under these overlapping linkage signals 
(19 Mbp to 49 Mbp) contains 433 genes including the transforming growth factor beta 1 
(TGFB1) gene, which plays a regulatory role in the proliferation and differentiation of many cell 
types.  Polymorphisms in the TGFB1 gene affect serum concentration levels (166), osteoclast 
formation, and resorptive activity (167), in addition to causing Camurati-Engelmann disease, a 
Mendelian skeletal disorder (168,169).  TGFB1, or one or more other genes in this region may 
contribute to the suggestive linkage signals on chromosome 19.  Two other suggestive QTLs 
(LOD > 2.0) were observed on chromosomes 2q12-14 (in men) and 14q11 (in the cohort >45 
years). 
  None of the possible QTLs identified in this study were observed in both baseline and 
follow-up samples.  Lack of replication between time points (in addition to modest evidence of 
linkage) hints that these suggestive QTLs may indeed be false positives.  Other possibilities for 
the inconsistent findings between baseline and follow-up include small effect sizes such that 
power to detect linkage is limited or gene × age (or -menopause) interactions such that the mean 
difference in age between time points attenuates power to detect linkage. 
The response of spine BMD to aging was modeled by adjusting follow-up measurements 
for baseline measurements.  Significant heritability (with variable point estimates) of this 
response was observed in the total sample, men, and subset >45 years of age, though no 
chromosomal regions were implicated.  This analysis is similar to and consistent with results 
showing heritability, but finding no evidence for specific QTLs, for annual change in spine BMD 
in this population (>45 years of age) (116). 
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Strengths of this investigation include the joint longitudinal and family-based study 
design, which has lent additional credence to replicated findings (i.e. heritable and environmental 
components of variance) and cast doubt on non-replicated findings (specific regions of linkage).  
Moreover, this approach has allowed us to assess the genetics of the response of spine BMD to 
aging, suggesting that genes may play a role in rate of change in spine BMD over time.  In 
addition, we have evaluated the genetic and environmental determinants of spine BMD in a 
population of Mexican Americans, who are underrepresented in the osteoporosis literature.  
Concomitant with these strengths, however, are several limitations, including the possibility that 
the high prevalence of osteoarthritis and aortic calcification, especially in men, may have inflated 
densitometric measurements of spine BMD in some participants (113-115).  Such noise may 
have reduced our power to detect linkage to spine BMD.  Also, while our sample size was 
sufficient to model spine BMD in men, women, and age-specific subsets separately (albeit with 
loss of power with respect to the total sample), we did not have adequate numbers to further 
partition our sample into more homogenous groups (e.g. pre- or postmenopausal women).  
Likewise, we did not specifically test for gene × environment interactions affecting spine BMD.  
Additional work is warranted to further investigate the proposed QTLs for spine BMD and 
clarify the role of genes in the response of spine BMD to aging.  Identification of the specific 
genes regulating spine BMD may provide important insights into our understanding of 
osteoporosis and may lead to better prevention and treatment of vertebral fractures.   
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7.0  CONCLUDING REMARKS 
7.1 MOTIVATION 
Considerable research has been done over the past four decades to identify both the genetic and 
environmental factors that influence bone health, especially peak areal BMD, and subsequent 
risk of developing osteoporosis.  However, much less is known about the genetic and 
environmental factors that affect longitudinal change in BMD and its impact on bone health, 
especially among younger men and women.  As part of this dissertation research, we investigated 
the genetic architecture of longitudinal change in BMD at several skeletal sites using data on 
large families of Mexican Americans, an understudied minority population.   
7.2 SUMMARY OF MAJOR FINDINGS 
The previous chapters of this dissertation detailed several important contributions of SAFOS to 
our understanding of the risk factors for osteoporosis.  Specifically, we determined that BMD 
change varied over time and could be categorized into two phases: early adult bone loss (in 
participants <45 years of age) and later bone loss (in participants >45 years of age).  Moreover, 
we showed that both of these phases of bone loss were significantly heritable at several skeletal 
sites, and identified environmental factors that influence bone loss.  We performed the first 
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autosome-wide linkage analyses for longitudinally-assessed bone change traits and identified a 
possible QTL for early bone loss on chromosome 1q.  By comparing genetic analyses of cross-
sectional BMD at baseline and follow-up, we identified QTLs with consistent effects on peak 
BMD of the hip and showed that QTLs influencing peak areal BMD did not overlap with QTLs 
influencing bone change. 
7.3 POINTS OF DISCUSSION  
One of the major hypotheses examined in this body of work was that genetic heterogeneity for 
rates of BMD change may exist for different phases of bone metabolism; that is, we 
hypothesized that distinct genetic factors may explain part of the variation in rate of bone loss in 
younger, compared to older, participants.  This idea was initially proposed based on the observed 
age-dependency of the trends in BMD and change in BMD in our sample (Figures 2.1 to 2.4) and 
in other studies (17,18,24,108,109), as well as genetic modeling showing age-specific genetic 
variance for rates of BMD change (Table 2.2).  This hypothesis was further supported by our 
heritability and linkage analyses of BMD change in family members <45 years and >45 years of 
age (Chapter 3 and 4).  For example, significant heritability was observed for BMD change of 
the hip and forearm in both age cohorts (h2r ranged from 0.31 to 0.44), and spine in the 
individuals <45 years of age (h2r = 0.42), whereas low heritability was observed in the total 
sample (h2r = 0.05 and p > 0.05 for skeletal sites of the hip and spine; h2r < 0.20 and p < 0.05 for 
sites of the forearm; results not shown).  Likewise, significant and suggestive QTLs observed for 
early bone loss in the cohort <45 years of age were not observed in the cohort >45 years of age, 
and vice versa (Figure 3.2 versus Figure 4.2).  For example, the strongest evidence of a QTL for 
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early bone loss was on chromosome 1q (LOD = 3.6), but there was no evidence of a QTL on 
chromosome 1 (maximum LOD = 0.80) for late bone loss.  Although our sample sizes for early 
and late bone loss are small, these findings support the assertion that effects of genes influencing 
rate of BMD change may differ, at least in the magnitude of their effect, across the adult lifespan. 
In contrast, genetic analyses of cross-sectional BMD (Chapters 5 and 6) did not differ 
between family members <45 years versus >45 years of age.  Heritability of cross-sectional 
BMD was similar between age cohorts and the total sample, and age cohort-specific QTLs were 
not observed.  These results are logical because current genetic models used in the analyses of 
cross-sectional BMD primarily reflect peak BMD acquisition.  The effects of genetic (and 
environmental) factors influencing variation in peak BMD should act only during adolescence 
and young adulthood (or earlier).  Therefore, the underlying determinants of peak BMD should 
not differ due to the age of the sample being analyzed as long as the analytical model used to 
recover peak BMD is accurate.  Any observed differences in the determinants of cross-sectional 
BMD between different age cohorts in the same population (i.e. family members <45 and >45 
years of age) would not truly be reflective of effects on peak BMD, but would instead be 
reflective of deviations in rates of change from the assumed age-trajectory of BMD.  Overall, 
these results show that analysis of longitudinal data, rather than comparing age-specific analyses 
of cross-sectional data, may be a better approach for finding genes influencing change in BMD. 
In addition to detecting possible QTLs that influence change in areal BMD, results of this 
project were also used to rank putative QTLs influencing peak areal BMD for future analyses.  
Although analysis of data collected on a largely overlapping set of individuals at a subsequent 
time point is not a true “replication”, those chromosomal regions showing linkage in both 
baseline and follow-up samples marshal stronger evidence of a true QTL than do chromosomal 
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regions showing linkage at only one time point.  Thus, among the three QTLs for peak hip BMD 
previously detected in a subset of the baseline sample, two of them (on chromosomes 6q and 
13q) were also detected in the follow-up sample, and are given higher priority for future 
investigation. 
 
 
Figure 7.1.  Multipoint LOD scores across chromosome 1 for:  change in femoral neck BMD in the cohort <45 
years of age (solid black line), change in total hip BMD in the cohort >45 years of age (dotted black line), baseline 
cross-sectional femoral neck BMD (blue line), and follow-up cross-sectional femoral neck BMD (red line).  
 
 
One of our most exciting results was the identification of a statistically significant QTL 
on chromosome 1q influencing early femoral neck bone loss in the cohort <45 years of age.  As 
described above, the QTL on chromosome 1q was not observed in analyses of BMD change for 
any skeletal site in participants >45 years of age, or in cross-sectional analyses of peak femoral 
neck BMD (or peak BMD of any other skeletal sites) at baseline or follow-up.  Although the 
sample size is modest, these results indicate that while the QTL on chromosome 1q may 
influence early bone loss, it does not have detectable effects on late bone loss or peak BMD in 
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our population.  Figure 7.1 compares multipoint LOD scores across chromosome 1 for BMD 
change in SAFOS participants <45 and >45 years, and cross-sectional BMD at baseline and 
follow-up.  Likewise, the replicated QTLs for peak hip BMD on chromosomes 6q and 13q were 
not observed for BMD change of any skeletal sites in participants <45 or >45 years of age. 
 
 
Figure 7.2.  Risk model for osteoporosis 
 
 
The investigations described in this dissertation were initiated under the risk model that 
osteoporosis and related heath outcomes are determined, in part, by the genes and environmental 
factors influencing peak BMD attainment in youth, and subsequent loss with age (Figure 1.1).  
Based on the results of this research, however, we have updated this risk model to include 
separate effects of genes and environmental factors on early-phase and late-phase bone loss in 
addition to the factors affecting peak BMD (Figure 7.2).  Although this research has provided a 
better understanding of the relative effect of genes and environmental covariates on early- and 
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late-phase bone loss in both men and women, numerous questions still remain, including what 
specific genes and gene × environment interactions are involved, and whether the risk model 
differs between sexes or among different ethnic or geographic populations.    
7.4 FUTURE CONSIDERATIONS 
The natural history of bone metabolism over the lifespan, and the parallel effects on bone health 
and BMD, are not entirely understood.  Thus, for studies of the underlying genetic and 
environmental architecture of BMD, such as this one, it is unclear what features of the data, 
including the timing of milestones or differences between sexes, age cohorts, populations, etc., 
may assist in devising the best way to analyze the data.  We have used a relatively simple 
approach—analyzing family members <45 years and >45 years of age separately—to investigate 
factors affecting BMD change.  Epidemiological work to more thoroughly characterize the 
changes over time in the architecture of BMD in Mexican Americans and other populations is 
needed to provide a better understanding of how these changes may impact different analytic 
approaches.  For example, the choice of age boundary to describe the involutive change in age-
dependency of BMD may differ by skeletal site or between sexes.  This information could be 
used to better plan analyses to search for genetic and environmental determinants of BMD in the 
SAFOS population.  Likewise, more advanced genetic models, which simultaneously consider 
the shared and unshared genetic determinants of phenotype variance among individuals younger 
and older than some age parameter could be developed to analyze BMD change. 
Methods that jointly model longitudinal measurements across time, and simultaneously 
determine the shared and unshared effects of genes on baseline BMD, early bone loss, timing of 
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involution, and age-related bone loss, could also be developed.  Rather than analyzing a single 
metric, longitudinal methods that can parameterize the trajectory of BMD over the adult lifespan 
may succeed in uncovering the roles of genes on bone metabolism.  Genetic modeling of this sort 
would likely require multiple follow-up measurements.  Reenrollment of SAFOS participants for 
collection of BMD data at additional follow-up time points could be used toward this end.  
Furthermore, an additional follow-up of SAFOS participants could also be used to increase 
sample sizes in age-specific cohorts for analyses parallel to those presented in this dissertation.  
For example, if individuals who were <45 years of age at baseline but >45 years at follow-up are 
recruited for one additional measurement (i.e. second follow-up), they would provide more 
observations, and could greatly increase power to detect possible QTLs affecting late-phase bone 
loss. 
Different avenues of research could be used to further investigate the putative QTLs 
influencing peak BMD and early bone loss identified in the preceding chapters.  In the upcoming 
months, genetic association of bone phenotypes will be performed for markers on the Illumina 
panel of 550K SNPs.  Evidence for association to polymorphisms in our positional candidate 
genes and linkage regions will be carefully scrutinized.  Genome-wide association analysis will 
be conducted in the search for other, novel, genetic factors affecting bone phenotypes.  
Functional analyses of any polymorphisms in genes showing association to bone phenotypes 
could also be pursued in vitro, and positive associations could be investigated in an independent 
population, such as the Amish. 
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7.5 PUBLIC HEALTH SIGNIFICANCE 
As part of this research, we demonstrated that many of environmental risk factors for low BMD 
and bone loss observed in other populations are also important for osteoporotic risk in Mexican 
Americans, a population that is currently under-represented in the bone health literature.   
Importantly, we also showed early and age-related bone loss was heritable, and obtained strong 
evidence for a putative locus affecting early bone loss on chromosome 1q.  Because osteoporosis 
is an enormous and growing public health problem, affecting approximately 30% of post-
menopausal women (2), and even higher proportions of the elderly (3), understanding the 
environmental and genetic influences on bone health may lead to better prevention, risk 
assessment, and treatment of osteoporosis.   
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